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PREVALENCE OF SLEEP RELATED BREATHING DISORDERS AND 
THE ASSESSMENT OF QUALITY OF SLEEP IN PATIENTS WITH 
CHRONIC HYPERCAPNIC RESPIRATORY FAILURE 
ABSTRACT 
Background: 
COPD will be the third leading cause of death by year 2020. In India, COPD 
and Post TuberculousSequelae  are very common chronic respiratory diseases  
that have significant morbidity and mortality.Sleep related symptoms occur in 
about 40% of cases in patients with COPD. Sleep related breathing disorders 
constitute the greatest number of disorders of sleep in patients treated by sleep 
medicine, pulmonary, and general practitioners in the outpatient setting. 
Aim : 
1.To know the prevalence   of sleep related breathing disorders (SRBD) in 
patients with Chronic Hypercapnic Respiratory Failure. 
2.To assess the  quality of sleep in patients with Chronic Hypercapnic 
Respiratory Failure. 
Material and Methods: 
Patients enrolled in the COPD registry at Government Hospital Of Thoracic 
Medicine  Tambaram,with  severe  stable  COPD  or  COPD  with  Pulmonary  
Tuberculosis Sequelaeare evaluated. Spirometry is done for those patients. 
Patients  with  FEV1<  40%  by  spirometry  are   included  ,  Arterial  Blood  Gas  
analysis is  done. Those with Chronic Hypercapnic Respiratory Failure are 
included in the study. Patients with similar degree of obstruction without 
Respiratory Failure are used as comparison group. Overnight Polysomnography  
was performed in those patients. Epworths Sleepiness Score and Pittsburg sleep 
quality index scoring is done. Data is analyzed by standard statistical methods. 
 
Results : 
FortyFive  patients are enrolled into the study in total. Thirty two patients are 
Patients with  ChronicHypercapnic Respiratory Failure (Group A). Thirteen 
patients had COPD or COPD with Pulmonary Tuberculosis  sequelae  and with 
similar degrees of airflow obstruction without Respiratory failure ( Group 
B).The mean Age group is 57.2 vs 57.8 years. Significant Nocturnal 
Desaturation is seen in 68.8% of patients with Group A and 38.5% of patients in 
Group B. Snoring is present in 41% of Group A and 23.07% of Group B. 
Obstructive Sleep apnea is seen in 2 patients in Group A (6.25%). Sleep latency 
(in minutes ) is  62.7 vs 42.4. arousal index is 31.1/hour vs 20.4/ hour,NREM1,2 
( in Minutes ) 208.1 vs 180.1, NREM3( Min ) is  20.7 vs  33.9 ,REM (min ) 
34.7 vs 48.6. In Group A, 68.8 % of patients  have significant nocturnal 
desaturation vs  38.5%  in Group B . Mean Epworth Sleepiness score is 11.5vs 
9.7,  MeanPSQI score is 13.2vs 7.3  
Conclusion : 
Nocturnal Desaturation is seen in significant proportion of patients with Chronic 
Hypercapnic Respiratory Failure (68.8%). 
There is good correlation between the Quality of sleep measurement by 
Pittsburgh Sleep Quality Index scoring and the sleep variables determined by 
polysomnography.  
 
Patients with Chronic Hypercapnic Respiratory Failure have decreased Total 
Sleep Time, Increased Sleep Latency, Decreased Sleep Efficiency, Decreased 
NREM Stage 3 Sleep, Decreased REM Sleep, Increased  Arousal, Increase in 
duration  of  Wake  after  Sleep  Onset  when  compared  to   normal  values  of  that  
age . Based on these variables it is concluded that Sleep Quality in patients with 
Chronic Hypercapnic Respiratory Failure is poor.  
 The prevalence  of sleep related breathing disorders (SRBD) in patients with 
Chronic Hypercapnic Respiratory Failure is 6.25% which is similar to that 
general population. 
KEY WORDS : Sleep related breathing disorders (SRBD), Quality of sleep 
Chronic hypercapnic respiratory failure, Polysomnography. 
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Human Beings spend almost 30% of their lives in sleeping. But 
still much attention has not been paid to sleep disorders. Only from the  
1970s, consequences of sleep disturbances produced by the abnormal 
breathing patterns, or Sleep Related Breathing Disorder (SRBD) are 
being recognized by the physicians. 
Sleep related symptoms occur in about 40% of cases in patients 
with COPD1. SRBD is associated with considerable morbidity. 
Obstructive Sleep Apnea (OSA) should  be considered in patients 
reporting daytime hyper somnolence irrespective of BMI or snoring 
history. 
The control of respiration in patients with chronic respiratory 
disease follows similar basic principles as that of the normal subjects, 
both during awake state and sleep, but with an expected lower feedback 
response during sleep2. 
In patients with chronic respiratory disease this lower feedback 
response affects the  nocturnal gas exchange and sleep quality  especially 
in those patients with  hypercapnia. The primary mechanisms of this 
include decreased ventilatory responsiveness to hypercapnia, decreased 
respiratory muscle output, and marked increases in the upper airway 
resistance3.  
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Sleep hypoventilation (SH) may be a  important factor in the 
development of hypercapnic respiratory failure in patients with chronic 
respiratory disease, particularly during rapid-eye-movement sleep, where 
marked respiratory muscle atonia occurs. This leads to increase in  sleep 
disruption, arousal, pulmonary hypertension, and is associated with 
higher mortality3. 
In India, COPD and Pulmonary Tuberculous Sequelae are very 
common chronic respiratory diseases  that have significant morbidity and 
mortality. 
Many patients develop chronic respiratory failure and the quality of 
life is very much affected. Intervention at various levels are needed to 
improve the quality of life of those patients.  
Sleep in those patients need to be paid more attention as the 
improvement in sleep quality will lead to improvement in the patients 
quality of life, as well as decreasing the morbidity. 
Sleep Related Breathing Disorders and the structural diseases of 
Lung can progress to cause Pulmonary Hypertension and Corpulmonale. 
Both Disorders can coexist as well.  
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This study aims at evaluating the sleep quality and the prevalence 
of sleep related breathing disorders in those patients so that interventions 
could be done to improve the quality of life in those patients. 
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Definition of Sleep  
Sleep is defined as period of bodily rest characterized by reduced 
awareness of the environment, a species-specific posture, and for most 
species, a particular sleep place4. 
Behavioural characteristics of the human sleep includes  
Absence or marked reduction in movement 
Decreased responsiveness to external stimuli (easy reversibility) 
Recumbent body position 
Closing of eyes 
Slow and regular breathing pattern  
The function of the sleep remains to be a subject of debate. Some 
authors have suggested that energy is being saved during sleep when an 
animal has nothing better to do.  
According  to  some  authors,  sleep  helps  in   the  consolidation  of  
memory and improved learning. As we know, one feels better or being 
restored after a good night’s sleep; but how and what have been restored 
is a subject of debate.  
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It is postulated that sleep is not just as a behaviour (similar to 
feeding, which happens only during wakefulness), but as a state that 
could also sub serve multiple functions (just as the waking state does). 
The dramatic difference in physiological differences between NREM and 
REM sleep suggest this hypothesis4. 
Proposed Functions 
Regulation of somatic growth (growth hormone release during 
NREM stages 3 and 4 sleep) 
Neural growth and processing 
Memory consolidation (REM sleep) 
Thermoregulation and Energy conservation 
Normal Sleep Requirements 
The total duration of sleep required every day varies from  
individual to individual and age-related differences are present . Most 
adults sleep for about 6 to 9 hours (average of 8 hours) during a night. 
Sleep duration for a period of  less than 5 to 6 hours per day is usually 
associated with the symptoms of sleep deprivation5. 
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Percentages of Sleep Stages in Healthy Adults6 
Sleep stage   Percentage of Total sleep time 
Stage 1 NREM  2–5% 
Stage  2NREM   45–55% 
Stage 3/4 NREM  5-20% 
Stage  REM    20–25% 
A sleep cycle is the period from NREM (Non Rapid Eye 
Movement) stages 1 to 4 to REM (Rapid Eye Movement) sleep. There are 
usually three to five NREM-REM sleep cycles, each occurring about 
every 90 to 120 minutes in adults (every 60 minutes in infants and young 
children) during the night. Each sleep stage is not necessarily seen in 
every sleep cycle. The duration of NREM stages 3 and 4 sleep is greater 
during the initial part of sleep, whereas REM sleep is relatively more 
common during the latter part of sleep.  
REM density (frequency of rapid eye movements during REM 
sleep) also increases during the latter portion of the night. Whereas 
NREM stages 3 and 4 sleep is related to the length of prior wakefulness 
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and  to  sleep  onset,  REM  sleep  is  related  to  circadian  rhythms  of  body  
temperature. 
Arousal threshold is the lowest during NREM stage 1 sleep (easiest 
to awaken) and is highest during NREM stages 3 and 4 sleep (most 
difficult to awaken)7. 
STAGE : WAKE 
Electroencephalography 
Lower frequency activity when a person is relaxed 
Prominent alpha (8–13 Hz) activity, when the person is drowsy and 
eyes are closed 
Low-voltage, high-frequency activity when the person is alert and 
as eyes are open 
Electro-oculography 
Slow rolling eye movements occurs when a person is drowsy and 
as eyes are closed  
Blinking or rapid eye movements occurs when the person is awake 
and alert. 
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Electromyography 
There will be high chin muscle activity (ie, high chin EMG 
amplitude) 
Associated features 
Alpha activity is generally more prominent in the occipital leads 
compared to the central leads 
Eye opening suppresses the alpha activity 
EEG and EOG tracings will be demonstrate muscle artefacts when 
the person is tense. 
Recording of occipital leads can help in the recognition of alpha 
waves as well as the timing of onset of sleep. 
STAGE 1 SLEEP 
Electroencephalography 
Low-voltage, mixed-frequency activity. 
Alpha activity occupies < 50% of the epoch. 
Prominent theta activity; beta rhythms may be present 
Absence of the sleep spindles or K-complexes. 
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Vertex sharp waves (high-amplitude, brief, negative deflections) 
will be present (more prominent in central leads). 
Electro-oculography 
No rapid eye movements. 
Occasional slow rolling eye movements. 
Electromyography 
High chin muscle activity is seen (ie, high chin EMG amplitude) 
that is less than or equal to that during wakefulness 
Associated features 
Occurs at sleep onset or following arousals from sleep. 
Person will be unresponsive but easily aroused. 
Accounts to about 2% to 5% of total sleep time in an adult 
Transitions into stage 2 sleep within a few minutes. 
STAGE 2 SLEEP 
Electroencephalography 
Low-voltage, mixed-frequency activity. 
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Delta activity will occupy < 20% of the epoch 
Presence of sleep spindles and K complexes (generally maximal 
over the vertex) 
Electromyography 
Low chin muscle activity. 
Electro-oculography 
No movements 
Associated features 
Accounts for the greatest proportion (45% to 55%) of total sleep 
time in adults. Three-minute stage 2 sleep scoring rule: Sleep spindles 
and K complexes are episodic and may not be present in every epoch. An 
epoch is scored as stage 2 sleep if the intervening period between sleep 
spindles or K complexes is less than 3 minutes, would otherwise meet 
criteria for stage 1 sleep (low-amplitude, mixed-frequency EEG), and is 
not associated with an arousal. An epoch is scored as stage 1 sleep if the 
intervening period is equal to or greater than 3 minutes. 
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STAGE 3 SLEEP 
Electroencephalography 
Sleep spindles may be present. 
Delta activity will occupy between 20% and 50% of the epoch. 
Electromyography 
Low chin muscle activity (usually less than that in stages 1 and 2 
sleep). 
Electro-oculography 
No movements 
Associated features 
Along with NREM stage 4 sleep, has the highest arousal threshold 
by external stimuli among the different sleep stages. 
Accounts for about 10% of total sleep time in an adult. 
Certain parasomnias (disorders of arousal such as sleep terrors or 
sleepwalking) usually occur during NREM stages 3 and 4 sleep. EEG 
amplitude of delta waves are increased  . 
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STAGE 4 SLEEP 
Electroencephalography 
Sleep spindles may be present. 
Delta activity occupies > 50% of the epoch. 
Electro-oculography 
No movements 
Electromyography 
Low chin muscle activity (generally less than that in stages 1 and 2 
sleep) 
Associated features 
Accounts for about 10% of total sleep time in an adult. 
Along with NREM stage 3 sleep, has the highest arousal threshold 
by external stimuli among the different sleep stages. 
Certain parasomnias (disorders of arousal such as sleep terrors or 
sleepwalking) occur during stages 3 and 4 sleep. 
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Amount of NREM stages 3 and 4, and EEG amplitude of delta 
waves are increased among adolescents and reduced in older adults.  
REM SLEEP 
REM  sleep  is  composed  of  two  components,  namely,  Tonic 
(without rapid eye movements) and Phasic (with rapid eye movements) 
sleep. 
Electroencephalography 
Saw-tooth waves will be present (more prominent over  vertex and 
the frontal leads). 
Low-voltage, mixed-frequency activity (theta and beta rhythms) 
Vertex sharp waves are not prominent. 
Alpha waves are 1 to 2 Hz slower than those occurring during 
wakefulness and NREM stage 1 sleep. 
Electro-oculography 
Bursts of the conjugate and rapid eye movements. 
No movements (tonic REM sleep) 
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Electromyography 
Amplitude of chin EMG are reduced or absent (ie, at least equal to 
or, more commonly, lower than the lowest amplitude during NREM 
sleep).Loss of postural muscle tone due to postsynaptic hyperpolarization 
of the spinal motor neurons7. 
THE INTERNATIONAL CLASSIFICATION OF SLEEP 
DISORDERS-2 (2005) (ICSD-2) classified the sleep disorders into six 
major categories8 : 
I. Sleep related breathing disorders 
II. Insomnia 
III. Parasomnia 
IV. Hypersomnias 
V. Circadian rhythm sleep disorder 
VI. Sleep related movement disorders   
Types of sleep-related breathing disorders 
Sleep-related breathing disorders  are classified into four major 
types9 
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1.Central apnea syndromes 
1. Primary Central Sleep apnoea 
2. Periodic respiration of high altitude 
3. Central sleep apneas without Cheyne-Stokes respiration secondary 
to other disorders (cardiac/renal disorders, malignant, vascular, 
degenerative or traumatic disorders of the central nervous system) 
4. Central apneas  due to medicine or other substances 
5. Cheyne - Stokes respiration 
6. Primary sleep apnea of the newborn 
2.  Obstructive Sleep apnea syndromes 
1. Obstructive Sleep apnea in adults 
2. Obstructive Sleep apnea in children 
3. Sleep associated Hypoventilation syndromes 
Hypoventilation/hypoxemia secondary to disorders of:  
Lung (e.g. COPD), or 
Vascular (e.g. Pulmonary Hypertension);  
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Neuromuscular ; Thoracic wall abnormalities;  
Obesity- Hypoventilation Syndrome, 
Idiopathic Non-obstructive Alveolar Hypoventilation 
Congenital Central Hypoventilation. 
4. Undefined/non-specific sleep disorders 
(Disorders without specific characteristics and where further 
investigation is required to allow their classification into any of the 
previous categories)9. 
Obstructive sleep apnea10 
The obstructive sleep apnea syndrome (OSAS) is present when the 
Apnea Hypopnea Index is greater than 5 to 10 events per hour and the 
patient have symptoms of excessive daytime somnolence, unrefreshing 
sleep, or chronic fatigue. 
Central Sleep Apnea  
Central sleep apnea (CSA) is less common than obstructive sleep 
apnea. 
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In Central sleep apnea there is temporary cessation of respiration. 
The Central command for the respiratory muscles are not present. It is 
characterised  by repeated episodes of apnea without respiratory muscle 
effort . 
Polysomnographic recording shows  absence of thoraco abdominal 
excursion and  nasal-oral airflow. 
Criteria: 
The individual must fulfill A, B, and C to be diagnosed with the 
central sleep apnea- hypopnea syndrome. 
A. At least one of the following symptoms that is not explained by 
other factors: 
Excessive daytime sleepiness 
Frequent nocturnal arousals/awakenings 
B. Overnight monitoring that demonstrates 5 to 10 or more central 
apneic events plus hypopneic events per hour of sleep. 
C. Normocarbia while awake (PaCO2 less than 45 mm Hg)10. 
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Upper airway resistance syndrome (UARS) : 
UARS   represent  a  milder  form  of  the  OSA  spectrum,  although  
there is debate whether or not UARS patients demonstrate different 
clinical and upper airway characteristics compared with OSA patients. 
UARS is not associated with apneas or significant oxyhemoglobin 
desaturations. The arousals result in sleep fragmentation and daytime 
sleepiness.  
Nonetheless, many patients with the upper airway resistance 
syndrome also have evidence for concomitant obstructive sleep apnea 
Risk Factors for Obstructive Sleep Apnea10 
Gender (male/female 2:1) 
Upper airway anatomy 
Obesity (>120% ideal body weight) 
Neck size (collar size >17 inches in males, >15 inches in females) 
Lateral peritonsillar narrowing 
Macroglossia 
Elongation/enlargement of the soft palate 
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Narrowing of the hard palate 
Tonsillar hypertrophy 
Nasal septal deviation 
Retrognathia, micrognathia 
Class III/IV modified Mallampati airway 
Specific genetic diseases, e.g., Treacher Collins, Downs 
syndrome, Apert’s syndrome, Achrodorophsia, etc. 
Genetic factors 
Endocrine disorders—hypothyroidism, acromegaly 
Alcohol, sedative or hypnotic use 
Conditions in which Sleep Apnea Should be Suspected : 
Systemic hypertension 
Obesity 
Myocardial infarction 
Cerebrovascular accident 
Pulmonary hypertension 
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Type II diabetes mellitus 
Nocturnal cardiac arrhythmias 
Driver involved in a sleep-related automobile crash 
Preoperative anaesthesia evaluation 
Consequenses of OSA 
1. Day Time Sleepiness leading to automobile accidents , decreased 
quality of life. 
2. Cardiovascular Diseases – Systemic Hypertension, Pulmonary 
Hypertension, Corpulmonale, Coronary Artery Disease, 
Congestive Cardiac Failure, Arrhythmia, Cerebrovascular 
Accidents 
3. Diabetes Mellitus 
Respiratory failure 
Respiratory failure is defined by failure of  the respiratory system  
in one or both of its gas-exchanging functions, oxygenation and carbon 
dioxide elimination from, pulmonary arterial blood11.  
Respiratory failure is divided into acute or chronic.   
21 
 
 
Distinctions between Acute and Chronic Respiratory Failure 
Category     Characteristic 
Hypercapnic respiratory Failure  PaCO2>45 mmHg 
Acute      Develops in minutes to hours 
Chronic      Develops over several days or  
      longer 
Hypoxemic respiratory failure  PaO2<55 mmHg when FIO20.60 
Acute      Develops in minutes to hours 
Chronic      Develops over several days  
      or longer 
Respiratory failure is  classified as hypercapnic or hypoxemic.  
Hypercapnic respiratory failure is defined as an arterial PaCO2 
(PaCO2 ) of greater than 45 mmHg.  
Hypoxemic respiratory failure is defined as an arterial PaO2 of less 
than 55 mmHg when the fraction of oxygen present  in inspired air (FiO2) 
is 0.60 or greater.   
Hypercapnic and hypoxemic respiratory failure coexist in many 
patients . Disorders initially causing hypoxemia may be later complicated 
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by respiratory pump failure and hypercapnia. Similarly, diseases that 
produce respiratory pump failure can be  complicated by hypoxemia due 
to secondary pulmonary parenchymal involvement. 
Acute hypercapnic respiratory failure is defined by a PaCO2 greater 
than 45 mmHg with accompanying academia (i.e. pH less than 7.30). The 
physiological effect of a sudden increase  in PaCO2 depends on the 
prevailing level of serum bicarbonate anion.   
In patients with chronic hypercapnic respiratory failure there is a 
long-standing increase in PaCO2 resulting in renal “compensation” 
causing increased serum bicarbonate concentration. A superimposed 
acute increase of  PaCO2 has a less clinical effect than does a comparable 
increase in patients with a normal bicarbonate level. 
Respiratory failure can result due to an abnormality in any of the 
following “effector” components of the respiratory system— the central 
nervous system, peripheral nervous system, respiratory muscles, the chest 
wall, airways, or alveoli .  
A defect in any of central nervous system, peripheral nervous 
system, respiratory muscles, the chest wall and airways, which constitute 
the “respiratory pump,” may cause coexistent hypercapnia and 
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hypoxemia. The disorders of the alveoli are more apt to result in 
hypoxemia initially11. 
Ventilatory Supply vs Demand  
The pathophysiology of hypercapnic respiratory failure is based on 
the relationship between ventilatory supply and ventilatory demand . 
Ventilatory supply   
The maximal spontaneous ventilation that can be maintained 
without development of respiratory muscle fatigue, which is  also known 
as maximal sustainable ventilation (MSV).  
Ventilatory demand is the spontaneous minute ventilation, when 
maintained results in a stable PaCO2 (assuming a fixed rate of CO2 
production). 
Ventilatory supply normally greatly exceeds ventilatory demand. 
So, major changes in the minute ventilatory requirements (e.g., during 
exercise) usually  occur without hypercapnia.  
In patients with lung disease, significant abnormalities will be 
present before ventilatory demand encroaches upon MSV. As result, 
hypercapnia is a late finding. 
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As ventilatory demand exceeds MSV, PaCO2 increases. The  
general rule is  MSV is approximated as one-half the maximal voluntary 
ventilation. Therefore, normally there is a 10- to 15-fold difference 
between resting ventilatory demand and MSV. 
Ventilatory pump accomplishes the bulk transfer of air to and from 
the alveoli. Hence, diseases that interfere with  the mechanical properties 
of  any  component  of  the  ventilator  pump   cause  disturbance  with  CO2 
elimination and O2 uptake. If disturbances in the function of the 
ventilatory pump are very severe, alveolar hypoventilation and 
respiratory acidosis may ensue. 
Diseases causing Hypercapnic Respiratory Failure do so by 
derangement in respiratory mechanics and lung dead-space volume (e.g., 
Chronic  Obstructive  Pulmonary  Disease  [COPD],  asthma,  or  
kyphoscoliosis) or by impairment in  the contractile properties of the 
respiratory muscles (e.g., neuromuscular disease).  
Chemoreceptor-induced increases in inspiratory and expiratory 
muscle activity are directly proportional to the severity of abnormalities 
in arterial blood gas tensions and represent a feedback control loop that 
restores arterial blood gas tensions toward normal by enhancing alveolar 
ventilation. 
25 
 
The magnitude of the changes in intrathoracic pressure and 
resistance and compliance of the airways are determined by these changes 
in respiratory motor activity.  
The maintenance of arterial blood gas tensions within a relatively 
narrow, normal range from new-born to senescence attests to the power 
of this homeostatic mechanism. 
Chemosensitivity induced increases in the respiratory activity also 
affects the timing of respiratory motor activity and this is  reflected in the 
duration of inspiration (Ti) and expiration (Te).  
Hypoxia and hypercapnia lead to decrease in  Ti and Te, resulting 
in the frequency of breathing to increase. Reductions in the Te are 
generally out of proportion to the reduction in Ti, thereby resulting in  
increase in the fraction of the respiratory cycle spent in inspiration.  
The partitioning of the respiratory cycle is represented by the Ti/Tt 
ratio, where Tt is the total duration of respiratory cycle.(i.e., the sum of Ti 
and Te). 
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Postinspiratory inspiratory activity (PIIA)  
The effects of Hypoxia and Hypercapnia on the activity of the 
inspiratory muscles after cessation of the inspiratory airflow ,so-called 
Postinspiratory inspiratory activity (PIIA) is different.  
Hypoxia increases PIIA in both the chest wall inspiratory muscles 
and the muscles that constrict  laryngeal aperture. Hence, hypoxia has a 
braking effect on the rate of expiratory airflow. The Te decreases with 
increasing hypoxic drive, resulting in increase in end-expiratory lung 
volume.  
PIIA causes  increase in lung volume, increase in the calibre of  
intrathoracic airways and increase in the O2 content of the lung. PIIA due 
to hypoxia affects the load on the respiratory muscles in a complex 
fashion  that is, PIIA due to hypoxia reduces inspiratory resistive work of 
breathing but causes increase in the inspiratory elastic and expiratory 
resistive work of breathing. The overall effect of hypoxia-induced PIIA is 
a reduction in the overall energy expenditure during breathing. In contrast 
to hypoxia, hypercapnia diminishes the duration of PIIA12. 
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Ventilatory response to Hypercapnia  
The ventilatory response to hypercapnia is determined by the 
prevailing level of PaO2 and is increased as PaO2 decreases. In fact, there 
is multiple interaction between the hypoxemic and hypercapnic stimuli  to 
enhance the inspiratory and expiratory motor activity.  
Worsening of hypoxemia enhances the hypercapnic ventilatory 
response  in accordance with the O2–CO2 interaction. The strength of a 
patient’s chemosensitivity to O2 and  CO2 ,  particularly,  to  the  O2–CO2 
interaction is a powerful feedback mechanism opposing the retention of 
CO2 in patients with ventilatory pump dysfunction. Hence , treatment of 
the hypercapnic, hypoxemic patient with supplemental O2 may cause 
decrease in Vt/Ti and Ti/Tt,resulting in worsening of hypercapnia . 
The rise of  PaO2 in hypoxic, hypercapnic subjects shifts the O2 
response to the right (less stimulus) predisposing  to hypercapnic 
respiratory failure  and shifts  the ventilatory response to hypercapnia to 
the right .  
28 
 
A higher CO2 stimulus is required to maintain ventilation at the 
baseline level in those patients. Accordingly, ventilation falls and the 
PaCO2 rises.  
The magnitude of the hypercapnia   in patients with COPD in acute 
respiratory failure induced  by supplemental O2 varies widely among 
subjects as it is determined by their chemosensitivity. 
Hypercapnia induced by supplemental O2 in the patients with 
COPD is multifactorial and reflects increases in the lung dead-space 
volume as well as reductions in alveolar ventilation.  
Hypoxia causes bronchoconstriction by increase in 
parasympathetic outflow to airway smooth muscle. Relief in hypoxemic 
stimulus causes bronchodilation and increased dead-space volume. 
Role of Blunted Chemosensitivity in Development of Respiratory 
Failure 
Hypoxemic and hypercapnic chemosensitivities  are inherited and 
there are ethnic traits that vary widely. Sensitivity of respiratory 
chemoreceptors  to both hypoxemia and hypercapnia declines with age.  
This decline in chemosensitivity with aging may explain why 
elderly patients with lung disease (e.g., COPD) or chest wall disease (e.g., 
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kyphoscoliosis) more frequently develop hypercapnic respiratory failure 
than the young adults.  
When the chemosensitivity is low, patients with diseases of the 
ventilatory pump are predisposed to development of hypercapnic 
respiratory failure 
The severity of airway obstruction required to cause CO2 retention 
in the patients with advanced COPD varies widely from subject to 
subject. Patients with a greatest respiratory effort response to the changes 
in PaCO2— as measured by the diaphragm EMG, the respiratory work of 
breathing, or the occlusion pressure—will have PaCO2 values closer to 
normal than the patients with blunted responses to CO2 but with the same 
severity of lung dysfunction. 
Hence, patients with diseases of the ventilatory pump with low 
chemosensitivity, are predisposed to the development of hypercapnic 
respiratory failure.  
However, since hypercapnia per se may blunt the response to acute 
rise in PaCO2, studies in patients with respiratory failure could not 
determine whether the blunted CO2 responses are a cause or a 
consequence of respiratory failure. 
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The tendency for chemosensitivity to be inherited has been used in 
a  number  of  subsequent  studies  to  assess  the  role  of  hypoxic  and  
hypercapnic responses in the pathogenesis of CO2 retention in the setting 
of obstructive lung disease.  
Study of relatives with normal lung function and blood gases has 
been employed to circumvent the effects of CO2 retention on respiratory 
chemosensitivity in patients with COPD. 
In general, normal relatives of hypercapnic patients with COPD 
have lower ventilatory responses to hypoxia and hypercapnia than 
relatives of eucapnic patients with COPD. 
In hypercapnic patients with COPD, it appears that the blunted 
chemosensitivities to hypoxia and hypercapnia are premorbid ventilatory 
pump and, thereby, stimulate mechanoreceptors in the ventilatory pump.  
The  diseases  of  the  airways  (COPD  and  Asthma)  or  chest  wall  
(Kyphoscoliosis) changes the resistance and compliance properties of the 
mechanoreceptor afferent inputs increase inspiratory neuromuscular 
output as reflected by the airway occlusion pressure in response to 
bronchoconstriction or external resistances or elastance.  
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The changes in ventilation during acute increase in airway 
resistance are inversely proportional  to changes in occlusion pressure. 
Hence, the magnitude of  motor response to increases in the respiratory 
load determines the ventilatory response. 
These ventilator responses are eliminated by general anesthesia and 
reduced in stages III and IV and REM sleep. 
The phasic and tonic inspiratory activity in the dilator muscles of 
the upper airway (e.g., posterior arytenoid, alaenasae, genioglossus), are 
increased in patients with hypercapnia and hypoxia.  
These increase in the activity of dilator muscles of the upper 
airway causes decrease in the load on the chest wall pumping muscles by 
decreasing the resistance to inspiratory airflow . 
The increased activity of these muscles further diminishes the 
susceptibility of  upper airway to collapse as the inspiratory efforts 
become greater and sub pharyngeal pressure becomes more sub 
atmospheric. 
Patients with COPD who are hyper inflated and dyspnoeic often 
assume a body posture that improves mechanical advantage of 
diaphragm, neck accessory, and pectoral girdle muscle. 
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The posture is  forward flexion of  the trunk,  with extension of  the 
head  and  neck  and   bracing  of  the  pectoral  girdle  by  rounding  of  the  
shoulders,  holding of the thighs with the arms.  
The net effect of this posture is  increase in abdominal pressure 
(thereby increasing diaphragm precontraction length and the radius of 
curvature) providing a more favourable alignment of the scalene and 
sternomastoid muscles with the upper rib cage; and also anchor the 
pectoral girdle muscles, thereby  allowing them to apply an inspiratory 
action on the rib cage. 
With this posture, transdiaphragmatic pressure is increased and 
diaphragm and sternomastoid muscle EMG activity is decreased12. 
Sleep Related Ventilatory Changes in  patients with  COPD: 
COPD  patients with day time hypoxia have the oxygen saturation 
level in the steep portion of oxyhemoglobin dissociation curve. These 
patients have much greater fall in the oxygen saturation during night 
Sleep Hypoventilation  
During all sleep stages, particularly during REM sleep the response 
of the respiratory centre are reduced  and the response of respiratory 
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muscle to respiratory centre outputs are also decreased, especially to 
those involving accessory muscles of respiration13,14 .  
In healthy individuals during REM sleep, ventilation may be 
decreased by 40% than during wakefulness. This is predominantly due to 
a reduction in tidal volume, and as a result of increase in the upper airway 
resistance and reduced  inspiratory drive, that causes  a slight decrease in 
arterial oxygen saturation (SaO2) that is clinically not significant in 
normal subjects15. 
Even though the breathing pattern is same as the normal subjects, 
the hypoventilation during sleep is exaggerated in patients with COPD16 . 
Exaggerated physiological dead space in COPD, which results in 
greater alveolar hypoventilation during sleep contributes to the profound 
nocturnal hypoxemia  than in normal subjects17.  
The  decrease in the basal metabolic rate and ventilatory 
requirements during NREM sleep causes   decrease in central respiratory 
drive. 
During REM sleep, there is decrease in   response of the respiratory 
centre to chemical and mechanical inputs18.  
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Previous studies in patients with COPD have documented  that a 
response of minute ventilation to rise in CO2 is lower even during 
wakefulness. 
Increased Resistance of Airways 
         The loss of muscle tone in the upper airways causes increased 
resistance for breathing during sleep19,20. Due to the increase in the 
resistance there is altered response in ventilation to hypoxia which results 
in hypoventilation. 
The Upper airway resistance in patients with COPD and normal 
subjects are similar but the airway dilation in response to hypercapnia is 
not seen in COPD patients. This contributes to the nocturnal desaturation 
in these patients20. 
During the normal circadian change in airway calibre there is mild 
bronchoconstriction during sleep. This bronchoconstriction may be 
increased during sleep in COPD. Therefore there is also an increased 
lower airway resistance21.  
Skeletal muscle tone is decreased during sleep. So the tone of 
intercostal muscles, tongue, pharyngeal muscles are reduced22,23.  
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There is presynaptic inhibition of afferent terminals from muscle 
spindles and supraspinal inhibition of  gamma- motor neurons and  the 
during the REM sleep.  
This inhibition results in decreased tone of intercostal muscles. The 
diaphragm is not affected by this because it is supplied by alpha motor 
neurons.  
Also there is decreased number of muscle spindles in diaphragm. 
As COPD patients are much dependent on the accessory muscles they are 
more affected during the sleep due to these changes. 
Hyperinflation of the Lung, one of the pathological consequences 
of COPD causes stretching of diaphragm that results in poor 
diaphragmatic contraction24. 
Patients with severe COPD have atrophy and skeletal muscle 
dysfunction, which may further result in reduction the contribution made 
by accessory muscles25.  
During sleep, supine position compromise the diaphragmatic 
efficiency as result of pressure by abdominal contents. 
In REM sleep diaphragm is the only muscle that is active in 
patients with COPD. 
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This probably explains why there are significant correlation 
observed between the factors related  to respiratory muscle strength and 
the mean nocturnal oxygen saturation  in COPD . 
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Emphysematous destruction of the pulmonary capillary bed and 
progressive airflow limitation results in ventilation perfusion mismatch in 
COPD. 
There is a reduction in Functional Residual Capacity, that occurs 
during sleep, as a result of decreased tone of the muscles and the 
increased resistance to the airways, which causes increase in the 
ventilation perfusion  mismatch26.  
In normal subjects, the supine position causes about 10% decrease 
in Functional Residual Capacity. 
The Small airways situated in the dependent part of the lungs gets 
closed due to the alterations mentioned above, which also causes the 
ventilation perfusion mismatch27. 
The degree of hypoventilation during sleep is similar in patients 
with significant nocturnal desaturation and those with minor nocturnal 
desaturation. This is proved by the fact that the increase in PaCO2 levels 
are identical in both groups28.  
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Effect of COPD on sleep quality  
Reduction in quality of life  is seen by patients with COPD due to 
Impairment of sleep quality29,30. These patients have complaints of 
fatigue, sleepiness, impaired concentration. 
When compared with the general population, there is increased 
prevalence of insomnia, hypnotic medications and  increased daytime 
sleepiness are seen in COPD 31. 
Patients with symptoms of nocturnal cough or wheezing have 
difficulty initiating or maintaining sleep. If both symptoms are present  
53% of COPD patients reported to have difficulty initiating or 
maintaining sleep, and 23%of COPD patients have excessive daytime 
sleepiness31. 
There is very little impact on sleep quality in patients with mild 
obstructive airways disease. But, as the COPD becomes more severe, 
there are increase in the number of complaints pertaining to sleep32 . 
Increased fragmention of sleep is seen in COPD, with increased arousals 
and decreased quantity of deep sleep and REM sleep33.  
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Correlation between hyperinflation and decreased sleep efficiency 
in overlap syndrome patients, was reported but this effect is independent 
of OSA after correction was made for the apnoea/ hypopnoea index 
(AHI). 
Hypercapnia seems to be the main factor behind the poor sleep in 
patients with COPD. This is reinforced by the fact that the sleep quality is 
not much improved by adding nocturnal oxygen34 . 
The  work  of  breathing  is  increased  in  COPD,  due  to  the  
hyperinflation .The stimulation of mechanoreceptors present in the  chest 
wall and lower airways are stimulated due to this increased work of 
breathing that results in increased arousals.  
The arousal response to increased inspiratory load is relatively 
preserved but the arousal response is lowest for hypercapnia and hypoxia 
in REM sleep.  
Symptom of nocturnal cough may be the cause for sleep 
disturbance in some patients. The use of drugs like Theophylline, used as 
a bronchodilator may also affect sleep quality.  
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Cigarette smokers have disturbances in the sleep due to effect of 
nicotine in cigarette smoke and the withdrawal may also cause the 
subjective experience of non-restorative sleep35. 
Sleep impairment is an important aspect in assessment of  the 
impact of COPD on the quality of life, but  this is frequently neglected by 
many physicians.  
Also, it has been shown that in COPD patients with sleep 
deprivation there is a  reduction in forced vital capacity (FVC) (about 
5%) and forced expiratory volume in 1 s (FEV1) (about 6%)36.    
OMACHI et al37 have demonstrated  that sleep disturbances can be 
predictive  of  COPD  exacerbations  and  mortality  of  COPD  patient.   
However, ITO et al38 have proved that depression is the independent 
factor predicting exacerbations and hospitalisation in COPD but not sleep 
disturbances. 
Overlap syndrome of COPD and OSA  
David Flenley was first to describe the ‘‘Overlap Syndrome’’ . He 
defined it as  the coexistence of COPD and obstructive sleep apnoea39 .  
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Administration of  nocturnal oxygen to these patients is questioned 
by him .The patients with Overlap Syndrome have worse clinical course 
and prognosis than those patients suffering from COPD or OSA alone. 
Epidemiology  
The diagnosis of COPD should always be considered in those 
patients who have symptoms of, chronic cough with sputum production 
and exertional dyspnoea, with history of exposure to risk factors for the 
disease (cigarette smoking).  
Post-bronchodilator FEV1/FVC < 0.70 by spirometry confirms the 
presence of persistent airflow limitation  and the diagnosis of COPD. 
OSA  is  considered  as  one  of  the  comorbidities  of  COPD.  Patients  with  
OSA develops recurrent upper airway collapse during sleep and there is 
cessation of respiration (apnoea).  
These events causes repetitive hypoxia and carbon dioxide 
retention, causing nocturnal awakenings (i.e. arousals) that restores the 
airflow. But as the sleep cycle starts again there is recurrence of  
obstruction and subsequent apnoea.  
Daytime sleepiness  or  nocturnal complaints are the usual 
presenting symptoms, but in many patients  the first to push for medical 
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evaluation comes from close companions due to the concerns regarding 
snoring and/or witnessed apnoea.  
Conformation of OSA is done by polysomnography.  
In  Chest  clinics,  COPD and  asthma  and  OSA are  the  commonly  
reported disorders. 
Studies have shown prevalence of nearly 4% in males and 2% in 
females in general population within the age group of 30 to 60 years40,41. 
COPD prevalence is dependent on the prevalence of tobacco 
smoking, but in general about 10% of the population in the world have 
moderate-to-severe COPD. 
Main risk factor for OSA is obesity and the rates of obesity have 
been on the rise since these studies were done. Hence, prevalence of OSA 
may be higher now. OSA occurred in 3% of mild COPD patients in a 
European study 43 
COPD and OSA 
In a recent COPD study about nocturnal symptoms states that 
about 78.1% reported to have some degree of night-time symptoms44.  
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This study  also reported to have increase in nocturnal symptoms 
with increase in the severity of airflow limitation .  
Patients having nocturnal symptoms have more exacerbations than 
patients without nocturnal symptoms. The OSA symptoms or sleep 
studies are not recorded in this study.  This is the main limitation of this 
study. 
Increased  arousals and difficulty in maintenance of sleep is seen in 
COPD patients with symptoms of nocturnal wheezing, cough and 
sputum. 
Reduction in total sleep time, sleep efficiency in COPD patients is 
documented in sleep studies , this causes the daytime hypersomnolence  
seen in  patients45. 
Significant nocturnal oxygen desaturation is seen patients with 
COPD and presence gas exchange abnormalities in daytime, particularly 
a lower PaO2 predictive of nocturnal oxygen desaturation.  
Previous studies documented that about 50% of COPD patients 
who have  daytime SaO2<90% without co-existing sleep apnoea have 
significant desaturation during sleep46. 
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There is an increased mortality in the patients who have significant 
nocturnal desaturation compared with those who do not desaturate . 
The  prevalence  of  OSA  is  found  to  be  similar  in  COPD  patients  
compared with the non-COPD population from the previous studies . But 
presence of some predisposing factors for OSA such as age, active 
smoking, oral corticosteroids, presence of peripheral oedema increases 
the risk of obstructive apnoea events.  
Obesity is the main risk factor for sleep disordered breathing, 
obesity hypoventilation syndrome, pulmonary hypertension and 
irrespective of the airflow obstruction severity in COPD patients . 
Management of Sleep Disturbances in COPD 
Nocturnal supplemental Oxygen therapy  
The most important complication that occurs during sleep 
hypoventilation is hypoxemia.  
Hypoxemia  when  corrected  alone  in  patients  with  COPD  with  
hypercapnia will result in worsening of ventilation because the 
chemoreceptor stimulation due to hypoxia gets abolished. Hence, when 
nocturnal oxygen is administered, 
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Thus, the supplementation should be targeted to bring the oxygen 
saturation level above 90%47.  
Mode of oxygen delivery during sleep is usually via nasal cannula 
because face masks are dislodged during sleep . 
The amount of time spent during sleep with less than 90% oxygen 
saturation is the main indicator for calculating the magnitude of 
hypoxemia. 
Medications 
There is increased cholinergic tone in night and it results in 
increased airflow obstruction and the deterioration in nocturnal gas 
exchange.  
Anti cholinergic agents like ipratropium has shown to improve 
sleep quality and nocturnal gas exchange in patients with COPD  
Improvement in nocturnal oxygen saturation with the once-daily 
anticholinergic agent, Tiotropium, is documented without much change in 
the sleep quality in one study48. 
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These agents cause significant changes  in oxygen saturation, 
particularly in REM sleep. This finding is significant  because it is during 
the  REM sleep there is more significant desaturation. 
Beta agonist salmeterol has shown improvement in oxygen 
saturation to same extent as that of Tiotropium49.      
Theophylline causes bronchodilation, increased contractility of 
diaphragm. It causes central respiratory stimulation. These effects are 
useful in COPD  patients having respiratory disturbance during sleep50.  
Theophylline has shown evidence of beneficial effects in OSA. But 
the disadvantage is the effect of this drug on sleep quality. 
Benzodiazepine and non-benzodiazepine hypnotics are shown to 
decrease sleep latency, decrease arousal frequency, improve sleep 
efficiency  but due to the effects of these drugs on ventilation causing 
hypoxaemia and hypercapnia. So it is recommended that these drugs  
should be avoided, in patients having  severe COPD.  
Use of hypnotics, such as zolpidem, has been documented in less 
severe COPD patients without having much impact on gas exchange 51 
Melatonin receptor antagonists, like ramelteon, is shown to 
improve sleep efficiency and shorten sleep latency. This drug have no 
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adverse effects on apnoea frequency or nocturnal oxygen saturation levels 
in patients with COPD52.  
Role of Non Invasive ventilation 
Patients with COPD  not responding to pharmacological therapy 
must be considered for non-invasive ventilation. Patients with COPD 
patients with hypercapnic respiratory failure should be considered for 
NIV. 
Improvements in respiratory muscle strength and endurance are 
reported in patients treated with NIV . 
NIV along with supplemental oxygen has shown improvement in 
quality  of  sleep  and  diurnal  PaO2 and PaCO2 levels  when  compared  to  
patients treated with supplemental oxygen alone . 
Mechanism of Action  
1. By reversing micro atelectasis and also preventing collapse of the 
airways causing reduction in the work of breathing and increases 
lung compliance. 
2. By giving  rest to chronically fatigued respiratory muscles results 
in improvement of daytime respiratory muscle function54. 
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Patients with diagnosis of  overlap syndrome should be treated by 
nocturnal pressure support . Decision between CPAP or Bi-level positive 
airway pressure can be determined on the basis of pattern of sleep 
disordered breathing.  
In patients where OSA predominates, Continuous Positive Airway 
Pressure (CPAP) may be the most appropriate, but in patients where there 
is significant nocturnal hypoventilation with associated periods of 
sustained hypoxaemia, Bilevel positive airway pressure may be more 
appropriate. 
Pittsburgh Sleep Quality Index (PSQI) 
Quality of sleep measurement can be done by the Pittsburgh Sleep 
Quality Index (PSQI).  
There are seven different domains like sleep latency, subjective 
sleep quality, habitual sleep efficiency ,sleep duration, use of sleep 
medication, daytime dysfunction sleep and disturbances over the last 
month. The client himself rates each of these seven domains of sleep. 
Based on the scores the Quality of sleep is measured. 
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The questionnaire has 19-items for evaluation of  subjective sleep 
quality over the past 1 month. Scoring of the answers is based on a scale 
of 0 to 3, whereby 3 reflects the negative extreme . 
The scores of these 7 components are added to obtain a global 
score that ranges from 0–21, with increasing scores indicating worse 
sleep quality.  
A global score of 5 or greater indicates a “poor” sleeper. Several 
research groups evaluated the clinical and psychometric properties of the 
PSQI. 
The  PSQI  has  a  specificity  of  86.5% and  sensitivity  of  89.6% for  
identifying cases with sleep disorder, with a cut-off score of 5.  
Epworth Sleepiness Scale (ESS)  
Epworth Sleepiness Scale (ESS) consists of 8 self-rated items, each 
item is scored from 0–3, that measures a patients habitual “likelihood of 
falling asleep” in situations of daily living. There is no specific time 
frame . 
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The ESS score ranges from 0–24, it represents the sum of 
individual items. Values >10 are considered to indicate excessive 
sleepiness depending on the situation. Values >15 are considered as 
excessive daytime sleepiness and the patient definitely needs medical 
evaluation.  
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Aim  
1. To know the prevalence   of sleep related breathing disorders 
(SRBD) in patients with Chronic Hypercapnic Respiratory Failure. 
2. To assess the quality of sleep in patients with Chronic Hypercapnic 
Respiratory Failure. 
Primary Objectives 
To estimate the prevalence  of Sleep Related Breathing Disorders 
(SRBD) in patients with Chronic Hypercapnic Respiratory Failure. 
To  know  the sleep quality  in patients with Chronic Hypercapnic 
Respiratory Failure. 
Secondary  Objectives 
To identify the risk factors for Sleep related breathing disorders in 
patients with chronic hypercapnic respiratory failure 
To identify correlation between the Quality of Sleep measurement 
by Pittsburgh Sleep Quality Index scoring and the sleep variables 
determined by polysomnography 
To estimate  the excessive daytime sleepiness by Epworth 
Sleepiness scale  in patients with Chronic Hypercapnic Respiratory 
Failure. 
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SITE OF INVESTIGATION 
Government  Hospital of Thoracic Medicine, Tambaram 
Sanatorium, Chennai 
STUDY PERIOD 
December 2013 to July 2014 
STUDY DESIGN  
Prospective Case control study  
SAMPLE SIZE 
45 patients  
Statistical analysis 
By using SPSS version 7 software – Independent t test, Chisquare 
analysis. 
Inclusion criteria  
1)  A  clinical  history  consistent  with  severe  stable  COPD  without  an  
exacerbation of airways disease for at least 4 weeks at the time of 
evaluation 
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2)  Patients  with  diagnosis  of  COPD  or  COPD   with  Pulmonary  
Tuberculosis Sequelae with  airflow obstruction  evidenced by Post 
bronchodilator Forced expiratory volume in one second (FEV1) of 
less than 40%  predicted, FEV1/forced vital capacity ratio of <0.70 
3) Patients with Chronic Hypercapnic Respiratory Failure is 
defined by daytime awake PaCO2> 45  mmHg  while  in  a  stable  
condition with PaO2>60 mm Hg and pH >7.350 are included in 
study group  and those with awake PaCO2< 45 mmHg  with 
PaO2>60 mm Hg and pH >7.350 are included in control group. 
4) Patients with  Systemic Hypertension, Diabetes Mellitus under 
control are included in the study. 
Exclusion criteria  
1) Patient with diagnosed  OSAS are excluded. 
2) Age >80 yrs. 
3) Patients with Cardiac, Hepatic and Renal Diseases. 
4) Patients with Uncontrolled Diabetes Mellitus  
5) Patients with Exacerbation < 4 weeks. 
6) Patients with Respiratory Acidosis. 
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7) Patients with history of Smoking and Alcoholism including 
those who left  within a period of less than 6 months. 
Methods 
Patients diagnosed to have COPD or COPD with Pulmonary 
Tuberculosis sequelae on  regular follow-up at Government Hospital of 
Thoracic Medicine, Tambaram are enlisted. Patients without history of 
exacerbation in the last 4 weeks are evaluated.  
1) Patients underwent Spirometric analysis and those with post 
bronchodilator FEV1 < 40% are asked for willingness to 
participate in the study. Those who are willing to participate  are 
screened for inclusion into the study. 
2) Informed Consent was obtained from all the patients 
3)  Arterial  Blood  Gas  analysis  was  done  for  those  patients  and  
Patients fulfilling the inculsion criteria are enrolled for study. 
Blood for Arterial Blood Gas analysis was drawn from radial 
artery, Analysis done in calibrated Blood Gas Analyser. 
4) Detailed History, symptoms of nocturnal cough, 
wheeze,history of lifetime alcohol, smoking  and clinical 
examination of patients done. 
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5) Height and weight were measured and BMI calculated, Neck 
circumference, Waist circumference measured.  
6) Respiratory Rate, Pulse rate, Blood pressure, Day time 
Oxygen saturation measured 
7) Blood was drawn for analysis of  Fasting and Post Prandial 
Blood Sugar, Blood Urea, Serum Creatinine, Liver  
Function Tests were done.  
8) Epworth Sleepiness Scale scoring, Pittsburgh Sleep Quality Index 
Scoring using Standard questionnaire is done.  
9) Patient was advised to avoid intake of caffeine on the day 
of study. He/She is refrained from having nap at daytime 
on the day of study. 
10) Patient was asked to go to bed one hour before the usual 
sleep time, hooking up of the polysomnogram instrument 
was completed and the lights are off at the usual sleep time 
and the recording was started.Full attended polysomnography 
was performed with Medicaid systems,  Sleep care SC 32 
Poysomnogram.  
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11) Recording was done for minimum period of 6 hours. Lights 
were put on once patient wakes up from sleep.  
12) Measured parameters are  electroencephalography (EEG), left and 
right electro-oculography, Thoracoabdominal movement by 
inductance bands, airflow ( by nasal pressure cannula), body 
position ,leg movements  and arterial oxygen saturation.  
13)  Polysomnography was done and the following sleep variables 
according to American Academy of Sleep Medicine (AASM) 
criteria are recorded. 
x Total Bed Time(TBT),  
x Total Sleep Time (TST), 
x Sleep efficiency,  
x Sleep latency,  
x Sleep stages in minutes and as percentage of TST,  
x Arousal index,  
x Respiratory event ( apnoea  and hypopneas) were measured in 
seconds. 
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x Apnoea-hypopnea index,  
x Minimal nocturnal oxygen saturation, 
x Mean nocturnal oxygen saturation and 
x Patients with nocturnal desaturation are recorded. 
Criteria for scoring based on American Academy of Sleep Medicine 
(AASM)55  
Apnea  
Apnea  is scored when there is a drop in the peak signal excursion 
by  90% of pre-event baseline  for  10 seconds 
The Apnea is scored as Obstructive if the above criteria with 
continued or increased inspiratory effort throughout the entire  period of 
absent airflow. 
The Apnea  is scored as Central if the above criteria is met with 
absence of inspiratory effort 
The Apnea is mixed apnea if  it begins as a central apnea, but 
towards the end there is effort to breathe without airflow. 
Hypopnea is diagnosed if all the following are present: 
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The peak signal excursions drop by 30% of pre-event baseline 
using  nasal pressure sensor. 
The duration of the 30% drop in signal excursion is 10 seconds. 
There is a  4% oxygen desaturation from pre-event baseline. 
AHI (Apnea Hypopnea Index) is the average number of apneas 
and hypopneas per hour of sleep. 
Cheyne Stokes Breathing  
Cheyne Stokes Breathing  is diagnosed if  there are atleast 3 
consecutive cycles of cresendo decrescendo change in breathing 
amplitude and atleast 1 of the following  
Five or more Central apneas or hypopneas per hour  
The cyclical  cresendo decrescendo breathing has duration of 
atleast10 consecutive minutes. 
Total Bed Time (TBT) is the time from Lights out to Lights on 
Total Sleep Time (TST)  is Total Stages N1, N2, N3, REM           
(in minutes) 
Total Sleep Time =Total Bed Time (TBT) – Total Wake Time 
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Wake After Sleep Onset (WASO) is the total amount of wake 
time after the first epoch of Sleep 
Sleep Efficiency (%) is the percentage of time asleep compared to 
the time spent in bed 
Sleep Efficiency (%) = Total Sleep Time (TST) ÷ Total Bed Time  
(TBT) x 100% 
% of Sleep Stages 
%  of  Sleep  Stages  is  the  Total  Time  of  a  particular  sleep  stage  
divided by Total Sleep Time (TST) This is calculated for Stages N1, N2, 
N3 & REM 
% Stage N1= Total Stage N1 (in minutes) ÷ TST x 100% 
 % Stage N2= Total Stage N2 (in minutes) ÷ TST x 100% 
 % Stage N3= Total Stage N3 (in minutes) ÷ TST x 100% 
 % REM= Total REM (in minutes) ÷ TST x 100 
Sleep latency is lights out to ¿rst epoch of any sleep stage  in 
minutes 
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Arousal is the total number of awakenings associated with 
transient desaturation compared to the preceding two minute period  per 
hour of sleep  
Arousal index is the average number of arousal per hour of sleep. 
Nocturnal Desaturation is defined by Patients with Oxygen 
saturation below 90 for > 30% of total sleep time9. 
Criteria for Obstructive  sleep apnea  
Individuals must fulfill criterion A or B, plus criterion C to be 
diagnosed with OSA: 
A. Excessive daytime sleepiness that is not explained by other 
factors 
B. Two or more of the following that are not explained by other 
factors: 
x Choking or gasping during sleep 
x Recurrent awakenings from sleep 
x Unrefreshing sleep 
x Daytime fatigue 
x Impaired concentration 
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C. Overnight monitoring demonstrates 5 to 10 or more obstructed 
breathing events per hour during sleep or greater than 30 events per 6 
hours of sleep. These events may include any combination of obstructive 
apnea, hypopnea. 
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Forty Five  patients are enrolled into the study in total. Thirty two 
patients are Patients with  Chronic Hypercapnic Respiratory Failure 
(Group A). Thirteen patients had COPD or COPD with Pulmonary 
Tuberculosis sequelae and with similar degrees of airflow obstruction 
without  Respiratory  failure  (Group  B  ).  In  Group  A  -Twenty  seven  
patients  were  male,  and  five   patients  were  female.  In  Group  A  -  22  
patients had COPD and 10 patients had COPD with Pulmonary 
Tuberculosis  sequelae . In Group B  - Ten Male and three patients were 
Female. Ten patients had COPD  and three had  COPD with Pulmonary 
Tuberculosis  sequelae. 
Table 1 
Baseline Characteristics  
Variables 
Group A (Mean + 
Standard Deviation) 
(n=32) 
Group B ( Mean + 
Standard 
Deviation) (n-13) 
Age 57.19 ± 8.56 57.85 ± 5.81 
Gender ( No. of Patients) Male - 27, Female - 5 Male - 10, Female – 
3 
Smoking Index ( Pack 
Years) 
29.09 26.92 
Life time Alcohol  
(No. Of Patients) 
8 2 
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Variables 
Group A (Mean + 
Standard Deviation) 
(n=32) 
Group B ( Mean + 
Standard 
Deviation) (n-13) 
Systemic Hypertension 
(No. Of Patients) 
8 3 
Diabetes (No. Of 
Patients) 
7 2 
Waist circumference 
( cm) 
80.47 ± 2.95 79.54 ± 6.70 
Neck Circumference 
( cm) 
34.09 ± 3.25 32.92 ± 1.93 
BMI 22.1 ± 3.4 21.3 ± 2.6 
FEV1/FVC 0.53 ± 0.08 0.57 ± 0.08 
FEV1% 26.78 ± 4.48 25.92 ± 4.05 
FEV1(L) 0.68 ± 0.28 0.72 ± 0.19 
FVC (L) 1.44 ± 0.35 1.25 ± 0.26 
PaO2 (mm) 65.03 ± 2.48 74.01 ± 3.46 
PaCO2(mm) 50.9 ± 3.15 38.55 ± 1.68 
pH 7.37 ± 0.05 7.39 ± 0.02 
HCO3(mm) 30.03 ± 1.21 25.66 ± 0.68 
Snoring(%) 41% 23.07% 
Nocturnal 
Awakenings(%) 
78.1% 69.0% 
Morning Headache(%) 41.0% 15.4% 
Chocking Episodes(%) 6.25% 0 
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(BMI-  Body  Mass  Index,  FEV1  –  Forced  Expiratory  Volume  -  1  
Second, FVC- Forced Vital capacity) 
Table 1 shows the baseline parameters of the Group A and B 
The mean Age group is 57.2 vs 57.8 years, BMI  is 22.1 ± 3.4  vs  
21.3 ± 2.6. Systemic Hypertension  is seen in 8 patients in group A and 3 
patients in Group B. Diabetes is seen in 7 patients in Group A and 2 
patients in Group B. Mean PaCO2  is 50.9 mm in Group A and 38.55 mm  
in Group B. Significant Nocturnal Desaturation is seen in 68.8% of 
patients with Group A and 38.5% of patients in Group B. Snoring is 
present in 41% of Group A and 23.07% of Group B 
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Table 2 
Independent  t test (Tests of Between-Subjects Effects) 
Comparison of Polysomnographic variables between Group A and B 
Polysomnography 
variable 
Group A  
(n-32) 
Group B 
(n-13) 
P 
Value 
Total bed (TBT) (in 
minutes) 
399.9 ± 35.3 419 ± 46.5 0.272 
Total sleep Time(TST) (in 
minutes) 
234.7 ± 33.6 290.9 ± 50.9 0.035 
Sleep latency 
(in minutes ) 
62.7 ± 18.5 42.4 ± 9.7 0.003 
Sleep efficiency % 58.5 ± 6.3 69.1 ± 8.4 0.042 
Arousal index (per hour) 31.1 ± 5.6 20.4 ± 5.6 0.003 
WASO ( Wake after sleep 
onset )          (in minutes) 
100 ± 23.9 84 ± 28.6 0.599 
WASO (% of TBT) 24.9 ± 5.3 20.1 ± 6.6 0.295 
AHI( Apnea hypopnea 
Index) 
3.19 + 2.13 2.4+ 1.7 0.987 
ESS score (Epworth 
Sleepiness Score) 
11.5+ 5.5 9.7 ± 4.2 0.219 
PSQI score(Pittsburgh 
Sleep Quality Index) 
13.2+ 1.9 7.3+2.1 0.018 
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Mean Values of Group A and Group B are presented in the Table 1 
and 2. Group A (Patients with Chronic Hypercapnic Respiratory Failure) 
Vs Group B ( Patients without Respiratory failure)   
The mean Total Bed Time (TBT ) (in minutes) is 399 + 35.3 vs 419 
± 46.5,  Total Sleep Time (TST) (minutes) is 234.7+ 33.6 vs 290.9 ± 
50.9. Sleep latency (in minutes ) is  62.7 ± 18.5 Vs 42.4 ± 9.7,  Sleep 
efficiency 58.5 ± 6.3 vs 69.1 ± 8.4,  Arousal index is 31.1 ± 5.6 vs 20.4 ± 
5.6, WASO ( Wake after sleep onset ) (in minutes) 100 ± 23.9 vs 84 ± 
28.6 . Epworth Sleepiness score is 11.5 + 5.5  vs  9.7  ±  4.2,  PSQI  is  
13.2+2.3 vs 7.3+2.1 .There is a statistically significant difference  in the 
Total Sleep Time, Sleep latency, Sleep efficiency, Arousal index and 
PSQI score between the two groups. 
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Table 3 
Independent  t test (Tests of Between-Subjects Effects) 
Comparison of Sleep Stages Between the Group A and B 
Sleep Stages 
Group A 
(n-32) 
Group B 
(n-13) 
P 
value 
NREM1,2 ( in Minutes ) 180.1 ± 29 208.1 ± 34.2 0.322 
NREM 1,2 (%of TST) 76.8 ± 5.7 71 ± 6 0.019 
NREM3( Min ) 20.7 ± 8.5 33.9 ± 15.4 0.002 
NREM3 (% of TST) 8.8 ± 3.4 11.4 ± 3.9 0.002 
REM (min ) 34.7 ± 7.8 48.6 ± 13.7 0.030 
REM (% of TST) 14.7 ± 3.2 16.7 ± 3.3 0.167 
 
 Table 3 showing various sleep stages among the two groups - 
NREM1,2 ( in Minutes ) 208.1 ± 34.2 vs 180.1 ± 29 . NREM3( Min ) is  
20.7 ± 8.5  vs  33.9 ± 15.4. REM (min ) 34.7 ± 7.8  vs 48.6 ± 13.7, There 
is  a  statistically  significant  difference   in  the  NREM1,2  (%),  NREM3(  
Min ), NREM 3(%), REM(min ) between the two groups. 
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Table 4 
Comparison of Oxygen Saturation between the Group A and B 
Oxygen Saturation 
Group A 
(n-32) 
Group B 
(n-13) 
P Value 
Daytime  SpO2 % 92.6 ± 1.6 93.8 ± 1.3 0.03 
Nocturnal  SpO2 % 85.3 +2.8 88.9 ± 2.9 0.001 
Minimal nocturnal SpO2 % 75.2± 5.4 79.4 ± 6.2 0.001 
Significant Nocturnal 
Desaturation(%) 
68.80% 38.50% - 
 
 Table 4 showing the Mean Day time Oxygen saturation 
during daytime, nocturnal and the minimal nocturnal Oxygen saturation 
with statistically significant difference in the two groups . Significant 
Nocturnal desaturation is defined by patients spending > 30% of Total 
sleep  Time  with  Oxygen  Saturation  of  <  90%  .   68.8  %  of  patients  in  
Group A have significant nocturnal desaturation, vs  38.5%  in Group B . 
 Picture Depicting the Difference between the symptoms in Patients 
with and without Respiratory Failure  
 
Picture Depicting the Difference between the Sleep Variables in 
Patients with and without Respiratory Failure  
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Table 5 
Prevalence of Sleep Related Breathing Disorders in Group A and 
Group B 
Sleep Related 
Breathing Disorders 
Group A 
No.of Patients ( %) 
Group B 
No.of Patients ( %) 
Obstructive Sleep 
Apnea  
2 ( 6.25%) 1 (6.66%) 
Central Sleep Apnea 0 0 
Mixed Sleep Apnea 0 0 
 
 Table5  Showing the prevalence of Obstructive Sleep Apnea in 
Group A is 6.25% vs 6.66 % in Group B .All the 3 Patients diagnosed 
with OSA in the cohort  had OSA of Moderate Severity (AHI 15 to 30).  
No patient was diagnosed with Central sleep apnea or Mixed apnea.  
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Table 6 
Comparison of sleep variables in Patients with Chronic Hypercapnic 
Respiratory Failure based on Symptoms of Nocturnal Cough + 
Wheeze 
Independent  t test (Tests of Between-Subjects Effects) 
Sleep variable 
Chronic 
Hypercapnia 
with  
Breathlessness 
(n=19) 
Chronic 
Hypercapnia with  
Breathlessness+ 
Nocturnal Cough 
+ Wheeze (n-13) 
P value 
Total bed Time (TBT) 
(in minutes) 
414.3 + 56.6 400.1+ 31.2 0.427 
Total sleep time (TST) 
(in minutes) 
285.6 +62.4 225.8 +26.1 0.003 
Sleep latency (in 
minutes ) 
48.3 +12.7 63.7 +20.0 0.021 
Sleep efficiency (%) 68.3 +8.0 56.6 +6.4 0.001 
Arousal index (Per 
hour) 
23.9 +7.1 32.0 +5.8 0.003 
WASO (in minutes) 79.9 +25.7 107.2 +22.0 0.006 
WASO (% of TBT) 19.4 +6.5 26.7 +4.7 0.003 
AHI (Apnea hypopnea 
Index) 
2.9 +1.6 2.5 +1.8 0.569 
PSQI score (Pittsburgh 
Sleep Quality Index ) 
9.3 +3.0 12.2 +2.8 0.012 
ESS score 11.0 +5.4 13.8 +5.2 0.180 
 
Patients with Chronic Hypercapnic Respiratory Failure with 
symptoms of Nocturnal Cough or Wheeze  had decreased Total sleep 
time(TST) 225.8  minutes, sleep efficiency 56.6%. They had increased 
sleep latency 63.7 minutes, arousal index 32.0/hr, WASO 26.7%, PSQI 
score 12.2,  ESS score of 13.8. Compared to patients without nocturnal 
cough or wheeze these patients have poor sleep variables. 
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Table 7 
Comparison of sleep stages in Patients with Chronic Hypercapnic 
Respiratory Failure based on Symptoms of Nocturnal Cough + 
Wheeze 
Independent  t test 
Sleep Stages 
Chronic 
Hypercapnia 
with  
Breathlessness 
(n-19) 
Chronic 
Hypercapnia with  
Breathlessness+ 
Nocturnal Cough + 
Wheeze (n-13) 
P Value 
NREM1,2 
( in Minutes ) 
209.5 +40.5 174.9 +28.2 0.016 
NREM 1,2(%of TST) 74.1 +6.8 75.5 +6.9 0.603 
NREM3( Minutes ) 29.8 +16.8 19.2 +8.2 0.048 
NREM3(% of TST) 10.0 +4.0 8.7 +3.8 0.377 
REM(min ) 46.2 +16.1 33.1 +7.2 0.012 
REM(% of TST) 15.8 +3.9 14.8 +3.2 0.461 
 
Comparison of sleep stages in Patients with Chronic Hypercapnic 
Respiratory Failure based on Symptoms of Nocturnal Cough + Wheeze 
shows statistically significant difference in NREM 3 duration and REM 
sleep duration between the groups. 
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Table 8 
Comparison of  Oxygen Saturation variables in Patients with 
Chronic Hypercapnic Respiratory Failure based on  Symptoms of 
Nocturnal Cough + Wheeze 
Independent  t test 
Oxygen 
Saturation 
Chronic 
Hypercapnia 
with  
Breathlessness 
(n-19) 
Chronic 
Hypercapnia with  
Breathlessness+ 
Nocturnal Cough 
+ Wheeze (n-13) 
P value 
Daytime SpO2 % 93.2 +1.4 92.2 +1.2 0.057 
Nocturnal SpO2% 87.5 +3.4 84.8 +2.8 0.038 
Minimal Nocturnal   
SpO2% 
76.3 +4.4 72.9 +5.2 
0.073 
 
There is statistically significant reduction in the mean nocturnal 
oxygen saturation (84.8%) of patients with Symptoms of nocturnal cough 
or wheeze. 
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Table 9 
Comparison in  Patients with Chronic Hypercapnic Respiratory 
Failure with Sleep efficiency of < 60 and >60  based on  Body Mass 
Index 
Sleep 
efficiency 
Body Mass Index ( No. Of patients ) 
Total 
< 18.5 18.5 - 24.9 25 - 29.9 > 30 
< 60 4 10 3 0 17 
> 60 1 11 2 1 15 
Total 5 21 5 1 32 
P -value 0.402 Chisquare   
 
There is no statistically significant correlation between the  Body 
mass index and sleep efficiency  based on the Chisquare analysis 
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Table 10 
Comparison in Patients with Chronic Hypercapnic Respiratory 
Failure with Sleep efficiency of < 60 and>60  based on  Systolic blood 
Pressure( mm Hg) 
Sleep 
Efficiency 
Systemic Hypertension 
Total 
Absent Present 
< 60 12 5 17 
> 60 12 3 15 
Total 24 8 32 
P -value 0.539 Chisquare  
 
There is no statistically significant correlation between Systolic 
blood pressure and sleep efficiency of patients with Chronic Hypercapnic 
Respiratory Failure 
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Table 11 
Comparison in  Patients with Chronic Hypercapnic Respiratory 
Failure with  Sleep efficiency of < 60 and >60  based on  Gender 
Sleep Efficiency 
Gender 
( No. of Patients ) 
Total 
Male Female  
< 60 14 3 17 
> 60 13 2 15 
Total 27 5 32 
P -value 0.737 Chisquare 
 
There is no statistically significant correlation between the  Gender 
and Sleep Efficiency  based on the Chisquare analysis. 
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Table 12 
Comparison of sleep variables in  Patients with Chronic Hypercapnic 
Respiratory Failure with  and without  Significant Nocturnal 
Desaturation 
Independent  t test 
Sleep variables 
Nocturnal Desaturation 
P 
value 
Present Absent 
Mean 
+Std.Deviation 
(n-22) 
Mean + 
Std. Deviation 
(n-10) 
Total bed (TBT) in minutes  413.9 +64.8 401.9 +32.9 0.490 
Total sleep time (TST) in 
minutes 
293.8 +69.2 236.5 +35.5 0.004 
Sleep latency (in minutes ) 47.2 +13.7 61.0 +18.1 0.014 
Sleep efficiency(%) 70.7 +8.3 58.6 +6.4 0.018 
Arousal index(per hour) 22.9 +7.9 29.6 +6.4 0.170 
WASO (in minutes) 72.2  +24.4 102.3  +21.2 0.001 
WASO (% of TBT) 17.6 +6.1 25.5 +5.0 0.001 
PSQI score 8.3 +3.4 12.0 +2.5 0.001 
ESS score 9.4+3.7 14.0+5.8 0.029 
 
This table shows that Patients with nocturnal desaturation have 
decreased TST, Sleep efficiency and increased Sleep latency, WASO (% 
of TBT),  AHI,  PSQIscore and  ESS score 
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Table 13 
Comparison of sleep stages in  Patients with Chronic Hypercapnic 
Respiratory Failure with  and without  Significant Nocturnal 
Desaturation 
Independent  t test 
 
Sleep Stages 
Significant Nocturnal 
Desaturation P 
Value 
No (n-10) Yes (n-22) 
NREM 1,2( in Minutes ) 215.7 +47.9 180.9 +27.5 0.014 
NREM 1,2 (%of TST) 71.3 +7.5 76.8 +5.8 0.031 
NREM 3( Min ) 33.0 +17.7 19.6 +9.4 0.009 
NREM 3 (% of TST) 10.9 +4.5 8.3 +3.3 0.065 
REM(min ) 47.7 +16.3 35.6 +10.8 0.018 
REM (% of TST) 16.4 +4.4 14.8  +3.3 0.259 
 
Table 13 shows that Patients with nocturnal desaturation have 
statistically significant Increase in duration of NREM 1,2 ( minutes) and 
% of NREM 1,2, decreased NREM 3 duration & decreased REM 
duration. 
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Table 14 
Comparison of sleep variables in  Patients with Chronic Hypercapnic 
Respiratory Failure with Epworth Sleepiness score of > 15 and < 15 
Independent t Test 
Sleep Variables 
Epworth Sleepiness score 
P value 
<15 > 15 
Mean +Std. 
Deviation                
(n-19) 
Mean + Std. 
Deviation         
(n-13) 
Total bed (TBT) (in 
minutes) 
403.2 +50.7 409.0 +35.3 
0.726 
Total sleep time(TST) (in 
minutes) 
266.9+59.9 236.1 +41.0 
0.119 
Sleep latency (in minutes ) 51.0 +14.6 64.8+19.5 0.029 
Sleep efficiency% 65.6 +8.7 57.6+7.0 0.01 
WASO (in minutes) 84.8 +28.2 104.5+17.4 0.033 
WASO (% of TBT) 21.2 +7.1 25.6 +4.1 0.054 
Arousal index (per hour) 25.4 +7.2 30.4+7.0 0.065 
PSQI score (Pittsburgh 
Sleep Quality Index) 
10.2+3.6 11.7 +2.4 
0.188 
 
This table shows that Patients with >15 have statistically 
significant reduction in  Sleep efficiency and increased Sleep latency, 
WASO (% of TBT),  AHI,  PSQI score . 
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Table 15 
Comparison of Sleep Stages in  Patients with Chronic Hypercapnic 
Respiratory Failure with Epworth Sleepiness score of > 15 and < 15 
Independent t Test 
Sleep Stages 
Epworth Sleepiness score 
P 
Value 
<15 > 15 
Mean + 
Standard 
Deviation (n-19) 
Mean + Standard 
Deviation (n-13) 
NREM1,2 ( in 
Minutes ) 
197.1 +42.6 183.8 +29.9 
0.34 
NREM1,2  ( % of 
TST) 
72.8 +6.3 78.4 +6.1 
0.017 
NREM3 ( Min ) 27.7 +14.5 17.9+10.6 0.045 
NREM3 (% of 
TST) 
10.1 + 3.8 7.4+3.2 
0.047 
REM (minutes) 42.7  + 13.43 34.46 + 13.05 0.092 
REM  (% of 
TST) 
16.07 + 3.46 14.17 + 3.75 
0.153 
  
Table 15 shows that Patients with ESS > 15 have decreased NREM 
3 duration and NREM % of TST, which is statistically significant. 
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Table 16 
Comparison of  Oxygen Saturation in  Patients with Chronic 
Hypercapnic Respiratory Failure with Epworth Sleepiness score            
of  > 15 and < 15 
Independent t Test 
Oxygen Saturation 
Epworth Sleepiness score 
P 
value <15  
(n=19) 
>15  
(n=13) 
DaytimeSpO2% 92.9 +1.3 92.3 +1.3 0.244 
Mean Nocturnal SpO2 % 86.8 +3.6 85.2 +2.3 0.163 
Minimal  Nocturnal 
SpO2% 
75.1 +4.5 74.0 +5.4 
0.546 
 
Patients with ESS > 15 have decreased Mean nocturnal SpO2  85.2 
% but the difference is not statistically significant. 
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Table 17 
Comparison of sleep variables in  Patients with Chronic Hypercapnic 
Respiratory Failure  
with Pittsburgh Sleep Quality Index Score of >10 and <10. 
Sleep Variables 
PSQI Score 
P value 
< 10 >10 
Mean +SD 
(n=14) 
Mean + SD 
(n=18 ) 
Total bed (TBT) In 
minutes  
415.9  +54.8 398.6  +35.9 
0.288 
Total sleep time(TST) in 
minutes 
291.5 +62.5 229.1  +29.1 
0.001 
Sleep latency(in minutes ) 44.9 +9.1 64.7  +18.1 0.001 
Sleep efficiency 69.4  +8.3 57.6  +5.8 0.001 
Arousal index( per hour) 22.0  +6.7 31.3  +5.4 0.02 
WASO (in minutes) 79.4 +23.3 102.0  +24.3 0.013 
WASO (% of TBT) 19.4 +6.4 25.5  +5.3 0.007 
DaytimeSpO2 % 93.3  +1.2 92.3  +1.3 0.035 
Mean NocturnalSpO2%  88.3  +3.5 84.8  +2.3 0.002 
Minimal Nocturnal  SpO2 75.4  +5.4 74.3  +4.6 0.531 
  
This table shows that Patients with PSQI >10 have decreased TST, 
Sleep efficiency and increased Sleep latency, WASO (% of TBT),  
Arousal index, mean nocturnal SpO2 % 
82 
 
 
Table 18 
Comparison of sleep stages in  Patients with Chronic Hypercapnic 
Respiratory Failure with 
Pittsburgh Sleep Quality Index Score of >10 and <10. 
 
Sleep Stages 
Pittsburgh Sleep Quality 
Index  (PSQI) Score 
P Value <10 >10 
Mean +SD 
(n=14) 
Mean + SD 
(n=18) 
NREM1,2  
( in Minutes ) 
214.0  +40.9 176.6  +27.9 0.004 
NREM 1,2 % of TST 72.3  +7.1 77.1  +5.9 0.046 
NREM 3( Min ) 30.1  +18.1 19.5  +7.7 0.029 
NREM 3 (% of TST) 9.8  +4.4 8.6  +3.4 0.368 
REM (min ) 47.3  +16.8 34.0  +7.7 0.005 
REM (%) 16.2  +4.0 14.7  +3.4 0.271 
 
This table shows that Patients with PSQI >10 have decreased 
NREM 3 and REM sleep duration, increased duration of NREM 1,2 
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Table 19 
Comparison of baseline characteristics  in  Patients with Chronic 
Hypercapnic Respiratory Failure with  and without OSA. 
Sleep Variable 
Chronic hypercapnic Respiratory Failure 
With OSA (n=2) With out OSA (n=30) 
 
P value Mean 
Std. 
Deviation 
Mean 
Std. 
Deviation 
Age( Years) 61.0 4.24 56.9 8.8 0.527 
BMI 27.8 0.74 21.6 3.1 <0.001 
Neck 
circeumference 
(cm) 
41 1.41 33.63 2.77 <0.001 
Waist 
circumference 
(cm) 
102.5 2.12 79 6.87 <0.001 
 
Table showing the baseline characteristics of Chronic Hypercapnic 
Respiratory Failure patients with and without OSA. There is a statistically 
significant difference in the two groups in BMI, Neck Circumference  and 
Waist circumference. 
 Picture Depicting the Difference between the Sleep Variables in 
Patients with Pittsburgh Sleep Quality Index  of<10 and >10 
 
Picture Depicting the Difference between the Sleep Variables in 
Patients with Respiratory Failure with and without OSA 
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Table 20 
Comparison of Sleep Variables in  Patients with Chronic 
Hypercapnic Respiratory Failure with  and without OSA. 
Sleep Variable 
Chronic hypercapnic Respiratory Failure 
With OSA (n=2) With out OSA (n=30)  
P 
value Mean Std. 
Deviation 
Mean Std. 
Deviation 
Total bed (TBT) (in 
minutes ) 
415.5 10.61 404.9 45.94 0.751 
Total sleep time (TST) 
(in minutes) 
238.5 41.72 255.5 55.67 0.677 
Sleep latency(in 
minutes ) 
74 14.85 55.53 17.65 0.160 
NREM1,2 
( in Minutes ) 
199.75 42.07 191.25 38.5 0.766 
NREM 1,2 (%of TST) 83.5 2.97 74.56 6.61 0.069 
NREM3( Min ) 11.5 4.95 24.61 13.84 0.196 
NREM 3(% of TST) 4.85 1.06 9.37 3.77 0.105 
REM(min ) 27 4.95 40.23 13.74 0.190 
REM (% of TST) 11.65 4.03 15.55 3.58 0.149 
WOSO (in minutes) 103.25 15.91 92.16 26.63 0.566 
WASO (% of TBT) 24.91 4.46 22.87 6.56 0.670 
Sleep efficiency 57.35 8.41 62.74 9.04 0.418 
Arousal index 32.55 2.76 27.15 7.59 0.330 
 
Table showing the sleep variables of Chronic Hypercapnic 
Respiratory Failure patients with and without OSA. There is decreased 
sleep time, sleep efficiency, Slow wave sleep, REM sleep in patients with 
OSA. There is increased Sleep Latency, WASO, Arousal Index. But 
difference is not statistically significant in the two groups based on sleep 
variables. 
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Table 21 
Comparison of Oxygen saturation in  Patients with Chronic 
Hypercapnic Respiratory Failure with  and without OSA. 
Oxygen Saturation 
Chronic hypercapnic Respiratory Failure 
With OSA 
 (n=2) 
With out OSA 
(n=30)  
P value 
Mean 
Std. 
Deviation 
Mean 
Std. 
Deviation 
Daytime SpO2% 91.5 0.71 92.8 1.32 0.184 
Nocturnal SpO2 % 84.5 2.12 86.33 3.35 0.453 
Minimal Nocturnal 
SpO2% 
74 4.24 74.77 4.97 
0.835 
AHI(Apnea hypopnea 
Index) 
15.5 4.1 2.51 1.77 
<0.001 
ESS score 21 1.41 12 5.32 0.025 
PSQIscore(Pittsburgh 
Sleep Quality Index) 
14 1.41 10.63 3.24 
0.160 
 
Table showing sleep parameters in Chronic Hypercapnic 
Respiratory Failure patients with and without OSA. Statistically 
significant difference is seen in AHI , ESS values. 
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The average age of  patients with  Chronic Hypercapnic 
Respiratory Failure (Group A)  is 57.2  years . Patients in Group A have 
slightly higher BMI  22.1  when compared to Group B (21.3) but this 
difference is not statistically significant. 
The Apnoea Hypopnea Index in Group A is higher than the AHI of 
Group B. But the difference is not statistically significant.  
The Prevalence of Sleep related Breathing Disorders  inpatients with  
Chronic Hypercapnic Respiratory Failure is 6.25% . For the whole cohort 
the prevalence is 6.66% . 
In General population  various studies reported prevalence of OSA  
around 5%56. In population of 50 – 70 year one study reported the 
prevalence as around  7 %57. Prevous Studies  in COPD patients reported 
prevalence OSA of around 10%58,59. The prevalence  of OSA in  patients 
with  Chronic Hypercapnic Respiratory Failure in our study  is similar to 
the previous studies . Our Study  results emphasizes the need for 
evaluation for OSA  in COPD patients presenting with Excessive daytime 
sleepiness. 
Sleep Hypoventilation Syndrome  is estimated to be around 43% in 
patients with Chronic Hypercapnia in previous studies60. In our study we 
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could not estimate the sleep Hypoventilation as Et co2 measurement was 
required. This is a limitation in our study.  
Obstructive Sleep Apnoea is diagnosed in 2 Patients in Group A 
and one in Group B. No case of Central or Mixed Sleep Apnoea is seen. 
Patients with OSA when compared to the other patients have 
higher Body Mass Index. All the 3 patients diagnosed to have OSA are 
Male patients with history of snoring. The Mean Neck Circumference and 
Abdominal Circumference is higher than the patients not having OSA. 
This  suggest  that  Patients  with  risk  factors  of  OSA  are  similar  to  those  
among the general population3. 
Results of our study suggest that COPD patients with Hypercapnia 
does not have  increased prevalence of SRBD, the prevalence is similar to 
general population. Even though the BMI of these patients are on the 
lower side, the risk for OSA remains the same. 
The average ESS score of patients with SRBD is much higher than 
the other patients with Chronic Hypercapnic Respiratory Failure. 
Excessive Day time sleepiness evidenced by ESS > 15 is seen in all the 
patients diagnosed with OSA. 
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The mean sleep time in Group A is 234.7 minutes which is lower 
than the patients in Group B. The sleep Latency is much higher in Group 
A  62.7, as against  42.4 minutes in Group B which is statistically 
significant. The sleep latency in patients with Chronic Hypercapnic 
Respiratory Failure in higher (62.7 min) than in other studies which 
showed Sleep latency of around 32 minutes61. There is statistically 
significant difference in  Sleep Efficiency of 58.5% in Group A  vs  
69.1% in Group B . The sleep efficiency of 75% is acceptable in study 
conditions according to previous studies but our study showed much 
decreased sleep Efficiency in patients with Chronic Hypercapnic 
Respiratory Failure61. Statistical analysis showed there is no significant 
difference in sleep efficiency of patients while comparing the patients 
Chronic Hypercapnic Respiratory Failure based on BMI, Sex, Systemic 
Hypertension. 
Arousal Index in Patients Chronic Hypercapnic Respiratory Failure 
is  31.1/ hour which is  higher  than Group B ( Patients without 
Respiratory Failure) is  20.4/hr, which is statistically significant. 
Wake  After  Sleep  Onset  (  WASO )  Is  24.9% of  total  bed  time  in  
Group A vs 20.1% in Group B. Even though there is increased WASO in 
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Group A There is no Statistically significant difference between the 
groups .  
Comparison of Sleep Stages shows that there is statistically 
significant difference in Mean NREM 1,2 in two groups . NREM 1,2 as 
% of TST  is higher in Group A than Group B. This shows increase in 
percentage of Stage 1,2 sleep in Patients with Chronic Hypercapnic 
Respiratory Failure. 
There is statistically significant difference in Mean NREM 3 % in 
two groups . NREM 3  as % of TST  is lower in Group A than Group B. 
This finding is similar to other studies in patients with COPD which 
suggest decrease in Slow Wave sleep in Patients with Chronic respiratory 
Failure61. Similarly REM sleep is decreased in Group A but there is no 
statistically significant difference between two groups. 
 Patients with Chronic Hypercapnic Respiratory Failure have 
decreased Total Sleep Time, Increased Sleep Latency, Decreased Sleep 
Efficiency, Decreased NREM Stage 3 Sleep, Decreased REM Sleep, 
Increased Arousal, Increase in duration of Wake after Sleep Onset when 
compared to  normal values of that age62.  
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Daytime SpO2%  in Group A is 92.6 %,Mean Nocturnal SpO2%  is 
87.9% which is lower than the comparison group which is statistically 
significant. Nocturnal Oxygen Desaturation is defined by reduction in 
Oxygen saturation  to less than 90% for  more than 30% of Total Sleep 
Time. Various studies on COPD shown that prevalence of Nocturnal 
Desaturation varies from 25 to 65 %63,64. In our study 68.8% of patients in 
Group A have nocturnal desaturation. Comparison between patients with 
and without nocturnal desaturation showed that the decreased quality of 
sleep in patients with nocturnal desaturation by measurement of PSQI and 
sleep variables in polysomnography. There is statistically significant 
decreased TST, Sleep efficiency, increased sleep latency , increased 
number of arousal, increased wake after sleep onset in patients with 
Chronic Hypercapnic respiratory failure . This study shows higher 
prevalence of Significant Nocturnal Desaturation in patients with Chronic 
hypercapnic respiratory Failure.  
The  ESS  score  of  >  10  is  considered  as  having  day  time  
sleepiness65. Score of >15 is considered as excessive day time sleepiness 
that needs medical evaluation. The Average ESS score of Patients with 
Chronic Hypercapnic Respiratory Failure 11.5. Excessive Day time 
sleepiness by ESS score of >15 is seen in 34.37% of patients with  
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Chronic Hypercapnic Respiratory Failure after excluding patients with 
OSA. High prevalence of Excessive day time sleepiness is expected in 
Patients with Chronic Hypercapnic Respiratory Failure but in our study 
shows that it is seen in only 34% and not all patients with hypercapnia 
have Excessive Day time sleepiness. 
Patients with ESS score of > 15 in Group A have decreased Total 
Sleep Time, decreased sleep efficiency, increased sleep latency, increased 
Wake after sleep onset, increased number of arousal.. There is a 
statistically significant decrease in NREM stage 3 Sleep. Patients with 
ESS score of >15 have lower mean nocturnal  Oxygen saturation. 
Pittsburgh Sleep Quality Index  of less than 5 is considered as poor 
sleep quality8. Our Study shows correlation between PSQI  and the sleep 
variables by polysomnogaphy. 93.75% of patients in Group A have PSQI 
of > 5. This indicates poor sleep quality in high number of patients with  
Chronic Hypercapnic Respiratory Failure. Comparing the patients with 
PSQI > 10 and < 10 patients with PSQI > 10 have statistically significant 
reduction in Total Sleep Time, decreased sleep efficiency, increased sleep 
latency, increased wake after sleep onset, increased number of arousal. 
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There is a statistically significant reduction in mean nocturnal Oxygen 
saturation. 
Patients with COPD and Pulmonary  Tuberculous  Sequelae have 
breathlessness as predominant symptom. Sleep quality is expected to be 
decreased in the presence of nocturnal cough with or without wheeze . 
This pattern is reflected in the results of our study which showed a 
statistically significant difference in Total sleep time, Sleep efficiency, 
sleep latency Wake After Sleep onset, Arousal index. The mean 
Pittsburgh Sleep Quality Index  is higher than the patients without 
nocturnal symptoms. Our study emphasises the importance of considering 
the symptoms of  nocturnal cough or wheeze while determining the 
quality of sleep in patients with Chronic Hypercapnic Respiratory Failure. 
Compared to  previous studies  done in  Pulmonary Tuberculosis 
Sequelae and COPD patients with respiratory failure by  Schonhofer et 
al66 and  S.K.Sharma  et  al67 , our patients had poor sleep quality with 
Sleep Latency of 62.7, and Sleep Efficiency of 58.5. The mean Apnea 
Hypopnea Index is higher 3.19 when compared to the previous study 
which is 1.8. 
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Conclusion of our study are 
1) Obstructive sleep apnoea is the Sleep Related Breathing 
Disorder diagnosed in patients with Chronic Hypercapnic 
Respiratory Failure.  
2) Prevalence   of   OSA   in  patients  with  Chronic  hypercapnic  
respiratory Failure  is 6.25%. The Prevalence of  OSA  is similar 
to the  prevalence in general population. Hence our study 
concludes that there is no increased risk for Obstuctive Sleep 
Apnea in patients  with Chronic Hypercapnic Respiratory 
Failure.  
3) Male gender, Increased BMI, Increased neck circumference and 
abdominal circumference are risk factors for OSA in patients 
with Chronic Hypercapnic Respiratory Failure which are similar 
to the general population.  
4) Patients with Chronic Hypercapnic Respiratory Failure have 
decreased Total Sleep Time, Increased Sleep Latency, Decreased 
Sleep Efficiency, Decreased NREM Stage 3 Sleep, Decreased 
REM Sleep, Increased Arousal, Increase in duration of Wake 
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after Sleep Onset when compared to  normal values of that age . 
Based on these variables it is concluded that Sleep Quality in 
patients with Chronic Hypercapnic Respiratory Failure is poor.  
5) Sleep stages in patients with Chronic Hypercapnic Respiratory 
failure show increase in NREM 1,2 and decrease in NREM stage 
3 and REM Sleep.  
6) Presence of symptoms of nocturnal cough  or wheeze  has 
significant impact in quality of sleep of the patients.  
7) Even though Excessive Daytime sleepiness is expected in 
majority of patients with Hypercapnia, Epworth Sleepiness score 
in our study shows  it is seen only in 34.37% of patients with 
Chronic hypercapnic respiratory Failure. 
8) Patients with Excessive Daytime sleepiness by Epworth 
Sleepiness scale scoring have more sleep impairment than those 
without Excessive Daytime sleepiness. 
9) Nocturnal Desaturation is seen in significant proportion of 
patients with Chronic Hypercapnic Respiratory Failure (68.8%).  
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10)  There is good correlation between the Quality of sleep 
measurement by Pittsburgh Sleep Quality Index scoring and the 
sleep variables determined by polysomnography.  
 
In summary the Sleep Quality of patients with Chronic 
Hypercapnic Respiratory Failure is poor, OSA is the Sleep Related 
Breathing Disorder diagnosed in those patients. The OSA prevalence 
rates are similar to those seen in the general population. There is good 
correlation between Pittsburgh Sleep Quality Index scoring and 
polysomnography in the diagnosis of Sleep Quality in patients with 
Chronic Hypercapnic Respiratory Failure. Our study suggests that poor 
sleep quality in patients with Chronic Hypercapnic respiratory failure. 
This may recommend the use of NIV even in stable severe COPD as 
recommended in some of the earlier studies, so that the sleep quality and 
the Quality of life could be improved. 
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PROFORMA 
Name: 
Age: 
Sex: 
OPno: 
IP no: 
Address: 
Duration of symptoms: 
Smoking; 
Alcohol: 
Last Hospitalisation: 
Medications: 
BP: 
Pulse: 
Spo2: 
ABG  : pH-              pCO2              PaO2-        Hco3-       Na-           k-          Cl-      
Neck circumference- 
Chest circumference 
Abdominal circumference- 
Ht- 
Wt- 
Bmi- 
comorbidities -                              
HB: 
CXR : 
PFT:
Clinical Diagnosis: 
Polysomnography: 
TST:
NREM 1 ; 
NREM 2: 
NREM 3: 
NREM 4: 
REM  : 
Respiratory effort related - Arousal Count: 
Movement : 
Position: 
Sleep Duration : 
Sleep Latency: 
Sleep Efficiency: 
SPO2 – DAYTIME: 
Spo2- NOCTURNAL: 
Minimum Nocturnal Saturation: 
Wakefulness after sleep onset : 
ObstuctiveApnoea: 
Central Apnoea ; 
Hypapnoea: 
AHI : 
ESS: 
PSQI Score : 
FINAL DIAGNOSIS: 
Sl.no Name age(years) sex Lifetime alcoholsymptoms smoking(pack years)bp pulse height(cm) weight(kg) BMI totalbed (TBT)in minutes time in bedtotalsleep time(TST)in minuteswoso (i  minutes)wasop (% of TBT)sleep latency(in minutes )NREM1,2( in Minutes )NREM %of TSTNREM3( Min )NREM% of TSTsleep efficiency%REM(min ) REM% arousal index/hour
1 Ponnamal 55 1 0 1 0 150/90 82 161 47 18.13 439 310 78.5 17.9 50.5 225 72.8 37 12 70.61 47 15.2 22.5
2 ladasamy 39 0 0 2 20 120/70 94 173 51 17.04 391.5 232.5 84.5 21.6 74.5 189.5 81.5 13.2 5.7 59.4 29.5 12.8 26.4
3 mookan 68 0 1 1 55 130/70 90 171 59 20.2 369 228 97 26.3 44 168 73.5 19 8.5 61.8 41 18 18.4
4 ponnu 41 0 1 2 35 120/80 88 161 55 21.21 362.5 217.5 96.5 26.6 48.5 171.5 78.9 17 7.8 60.4 29 13.3 28.6
5 kuppusamy 60 0 1 1 64 110/80 103 161 55 21.21 364 218 76.5 21 69.5 153 70.1 22.5 10.4 59.8 42.5 19.5 21.8
6 ethiraj 55 0 0 1 50 100/60 94 162 64 24.3 310 201 46.5 15 54.5 160 76.7 25 12 67.41 42.5 20.3 32.8
7 gopal 61 0 0 2 30 110/80 89 171 61 20.8 384 279 74.5 19.4 30.5 232.5 60.5 14.5 5.1 72.6 32 11.5 22.6
8 balu 64 0 0 1 60 150/90 88 158 68 27.3 423 268 92 21.7 63.5 229.5 85.6 15 5.6 63.3 23.5 8.8 30.6
9 gandhi 65 0 0 1 35 100/80 91 158 55 22.03 369 243 67.5 18.3 58.5 185 76.13 10.5 4.3 62.33 47.5 19.5 30.1
10 kupana 55 0 1 1 33 130/70 78 159 55 21.75 411.5 273 98.5 23.9 39.5 185 67.8 37 13.6 66.37 50.5 18.6 15.9
11 saroja 55 1 0 1 0 130/70 78 160 54 20.09 401.5 277.5 88.5 22 34.5 190 68.4 37 13.4 66.37 50.5 18.2 15.9
12 kanagaraj 69 0 0 1 50 150/90 94 164 48 17.8 528 380.5 93.5 17.7 54.5 281.5 74 62.5 16.5 72.06 36.5 9.5 26.4
13 kittu 52 0 1 2 38 130/70 94 167 58 20.7 417 241.5 124 29.7 51.5 196 81.2 16.5 6.8 58 29 12 38.2
14 muthusamy 61 0 1 2 41 110/80 85 161 60 23.14 408 224.5 119.5 29.3 64 168 74.8 36 16 55.02 36 16 29.6
15 muniyan 63 0 0 1 31 100/60 80 161 58 22.37 411 273 94 22.9 44 212.5 82.5 17 6.2 66.4 41 11.3 28.3
16 kabali 65 0 0 2 28 100/70 81 155 60 24.97 371 213 104 28 54 164 77 15 7 57.5 38 18 33.7
17 perumal 58 0 0 1 30 140/80 85 164 76 28.35 408 209 114.5 28.1 84.5 170 81.4 8 4.1 51.4 30.5 14.5 34.5
18 muthaye 58 1 0 1 0 110/80 94 140 61 30.68 445 297 92 20.7 56 224 75.5 28 9.5 66.2 44.5 15 31.1
19 puusothaman 61 0 0 1 45 150/90 91 173 63 20.38 401 257.5 105 26.2 38.5 164 63.8 40.5 15.7 64.28 52.5 20.5 17.1
20 malliga 56 1 0 2 0 120/80 91 148 58 26.4 382 215.5 110 28.8 56 149.5 69.4 24 11.2 56.4 42 19.4 32.4
21 kasi 63 0 0 2 51 110/70 88 169 63 22.05 403.5 236 107 26.5 60.5 171 72.3 28.5 12.1 58.48 36.5 15.6 14.8
22 aasaithambi 52 0 0 1 30 130/80 85 168 59 20.9 388 314 31.5 8.1 42.5 254.5 81 18 5.8 80.92 41.5 13.24 15.5
23 nandan 48 0 1 2 23 130/80 88 165 48 17.63 391.5 203 132 33.7 56.5 164.5 81 17 8.4 51.9 21.5 10.6 31.5
24 kuppan 58 0 0 2 0 140/90 93 168 59 20.9 419 233 137 32.7 49 184 79 21 9 55.6 28 12 38.1
25 velu 58 0 0 1 30 110/80 90 172 59 19.9 512 409 57 11.1 46 278.5 68.12 51 12.4 79.8 79.5 19.5 15.1
26 kamala 57 1 0 2 0 120/80 80 164 48 17.84 440 270.5 125.5 28.5 44 184.5 68.2 36.5 13.6 61.48 47 17.5 20.8
27 karupan 52 0 0 2 30 110/60 95 170 61 21.1 407.5 218.5 120.5 29.6 68.5 171.5 78.5 17.5 8 53.6 29.5 13.5 22.6
28 ranganathan 68 0 0 1 58 140/70 96 164 51 18.7 428 327.5 62.5 14.6 38 206.5 63 52.5 16.5 76.5 68.5 21 16.4
29 chinasamy 50 0 0 1 31 130/60 94 158 45 18.02 388 228.5 88.5 22.8 71 145 63.45 25 11 58.5 33.5 14.6 31.4
30 arokyam 48 0 0 2 15 110/80 90 163 63 23.71 391 229.5 84.5 21.6 77 146.5 64 34.5 15 58.69 48 21 36.4
31 ponnima 52 1 0 2 0 120/60 90 145 54 25.6 388 170.5 76.5 19.7 91 125.5 73.6 17 10 43.9 28 16.4 39.4
32 durai 58 0 1 1 21 140/90 89 160 50 19.53 407.5 244 110 27 53.5 201 82.5 13.5 5.5 59.87 29 12 29.3
33 elumalai 50 0 0 1 39 130/80 88 168 48 17.01 369.5 209.5 91.4 24.7 68.5 165.5 79 20.5 9.4 56.63 24.5 11.6 21.4
34 kandan 64 0 0 1 34 110/60 90 171 65 22.22 485 302.5 98 20.2 45.5 226 74.8 33 11 62.57 43 14.2 16.8
35 rathinam 61 0 1 2 30 110/80 87 155 58 24.14 488 294 152.5 31.3 41.5 222.5 75.6 23.5 8 60.24 48 16.4 25.9
36 selvan 70 0 0 1 44 100/70 91 163 70 26.3 385.5 266.5 83.5 21.7 35.5 202.5 75.9 28 10.5 63.19 36 13.6 36.4
37 soundaran 47 0 0 1 22 130/80 91 159 55 21.7 469.5 333.5 96.5 20.6 39.5 212 63.7 50 14.9 71.5 71.5 21.4 13.4
38 mohan 49 0 0 1 49 130/80 79 169 55 19.25 401 327 45 11.2 29 210.5 64.4 49 15 81.5 67.5 20.6 19.5
39 kandasamy 55 0 0 2 29 120/80 67 163 49 18.42 389 309 54.5 14 25.5 221 71.5 43 14 79.4 44.5 14.5 21.9
40 muniyappan 57 0 0 1 0 110/70 79 159 56 22.15 445 367 49 11 29 238 65 62 17 82.4 66 18 20.8
41 raghu 50 0 0 1 35 140/70 83 143 49 23.9 384 279.5 59 15.4 45.5 201 71.91 33 11.8 72.78 45 16.1 14.8
42 rakaye 54 1 0 1 0 110/80 93 141 52 26.1 421 325.5 64.5 15.3 31 228 70 39 12 77.31 58.5 18 16.1
43 kannaka 60 1 0 1 0 140/90 96 151 49 21.49 382.5 225.5 131 34.2 26 175 77.6 14.5 6.4 58.98 36 16 29.67
44 ponraj 68 0 0 1 38 139/70 94 158 59 23.63 386 272 71.5 18.5 41.5 213.5 78.6 20 7.4 70.46 38.5 14 21.4
45 kutty 72 0 1 2 55 150/80 88 170 62 21.4 488 257.5 130 26.6 106.5 211 82 6.5 2.5 52.7 40 15.5 36.4
SEX   0- Male , 1- Female
Lifetime Alcohol 0- Absent, 1- Present
Symptoms   1- Breathlessness, 2-  Breathlessness + Wheeze
Diagnosis   1- COPD with Respiratory Failure ,2- COPD with PT Sequelae Respiratory Failure, 3-COPD with respiratory Failure With OSA,4-  COPD with out Respiratory Failure ,5-COPD with PT Sequelaewithout Respiratory Failure,6-COPD without Respiratory Failure with OSA,
Diabetes 0- absent, 1- present
Snoring 0- absent, 1- present
Chocking, 0- absent,1- present,
nocturnal awakenings, 0- absent, 1- present.
dignosis daytime Spo2 %nocturnal spo2 %minimal nocturnal spo2Nocturnal DesaturationAHI ESS score PSQIscore pH Paco2 PaO2 HCO3 FEV1% FEV1(L) FVC(L) FEV1/FVC Neck Circumference(cm)Waist  Cir umference(Cm)Diabetes Snoring Nocturnal AwakeningMorning HeadacheCho king Episodes
4 96 91 88 1 2.5 11 11 7.426 35.59 80.65 25.67 20 0.7 0.88 0.62 33 73 0 1 0 0 0
2 92 86 80 1 0 21 12 7.362 50.86 61.38 30.47 23 0.87 1.46 0.6 32 74 0 0 0 0 0
1 93 90 71 0 0 8 7 7.368 47.4 66.89 29.67 28 0.8 1.77 0.45 35 75 0 0 1 0 0
2 94 85 81 1 3.1 5 7 7.619 48.9 67.54 28.72 29 0.93 1.9 0.48 34 78 0 0 1 0 0
1 94 85 79 1 0 8 14 7.368 48.6 68.43 30.43 23 0.64 0.91 0.7 32 70 1 1 1 0 0
1 92 90 78 0 4.4 12 12 7.361 48.84 62.87 29.4 31 0.9 1.66 0.54 34 85 1 1 1 1 0
1 94 91 68 0 0 9 9 7.354 50.4 64.86 32.41 35 1.08 2.07 0.52 35 77 0 0 1 1 0
3 92 86 71 1 12.6 22 13 7.356 55.62 64.78 30.21 25 0.61 1.102 0.55 42 104 0 1 1 1 1
1 93 80 71 1 3.8 11 9 7.361 49.84 70.84 28.67 21 0.5 1.16 0.43 33 71 0 1 1 0 0
4 93 91 83 0 2.1 8 5 7.377 37.76 74.41 25.53 33 0.83 1.25 0.66 30 72 0 0 1 1 0
5 93 87 83 1 2.1 8 5 7.377 37.76 74.41 25.53 25 0.52 0.86 0.6 35 80 0 0 1 0 0
1 93 91 73 0 4.1 6 5 7.364 49.4 64.88 31.2 34 0.87 1.93 0.45 33 73 0 0 0 0 0
1 91 84 69 1 3.1 16 15 7.354 56.54 65.43 30.85 24 0.76 1.35 0.56 31 77 0 1 1 1 0
1 92 81 70 1 0 11 14 7.365 54.67 64.56 32.21 22 0.58 1.18 0.48 34 84 0 1 1 1 0
1 94 85 74 1 2.8 18 14 7.355 50.54 63.86 29.68 24 0.62 1.06 0.58 31 75 0 0 1 1 0
1 91 83 71 1 3.8 17 12 7.364 48.67 68.42 28.19 30 0.68 1.45 0.6 36 85 0 0 1 0 0
3 91 83 77 1 18.4 20 15 7.366 56.5 62.45 31.44 30 0.86 1.432 0.6 40 101 0 1 1 1 1
1 91 84 75 1 4.6 8 13 7.351 50.87 63.45 30.69 25 0.47 1.02 0.46 43 98 1 1 1 0 0
4 94 89 83 1 3.7 7 9 7.385 38.56 70.48 26.78 22 0.69 1.07 0.64 31 81 0 0 1 0 0
1 93 84 71 1 4.1 19 10 7.356 56.67 64.09 31.45 24 0.5 0.93 0.64 38 83 1 0 1 1 0
4 95 87 81 1 0 14 7 7.368 36.48 73.88 24.5 22 0.69 1.5 0.46 32 78 0 0 1 0 0
1 93 90 80 0 0 4 5 7.361 47.89 64.47 28.9 30 0.96 1.93 0.5 34 81 1 0 0 0 0
2 92 85 65 1 0 19 11 7.358 50.59 63.86 29.48 21 0.67 1.28 0.52 30 77 0 0 1 1 0
2 91 83 78 1 4.4 7 11 7.354 51.54 63.45 30.16 19 0.59 0.86 0.68 35 74 0 0 1 1 0
1 94 91 78 0 3.2 9 6 7.365 48.54 64.98 28.78 33 1.06 2.16 0.49 30 77 0 0 0 0 1
4 96 90 88 0 3.4 10 10 7.408 40.78 73.09 24.87 29 0.55 1.52 0.55 32 77 0 0 1 0 0
2 94 83 74 1 3.9 8 17 7.358 54.58 63.43 30.48 19 0.62 1.63 0.4 35 76 0 1 1 1 0
1 94 90 71 0 4.1 7 8 7.368 49.52 68.42 29.87 28 0.77 1.28 0.6 31 72 0 0 0 0 0
2 95 84 71 1 3.6 11 11 7.361 47.78 68.89 28.76 30 0.92 1.53 0.6 30 70 0 0 1 0 0
2 92 90 69 0 4.8 13 16 7.362 49.48 62.61 31.48 31 0.91 1.42 0.68 37 80 0 1 1 0 0
1 92 85 80 1 2.8 17 13 7.359 56.67 65.9 29.61 28 0.63 1.14 0.55 34 88 0 1 1 1 0
2 93 91 71 0 3.3 17 8 7.359 48.58 64.48 29.37 30 0.92 1.73 0.53 31 73 0 0 1 0 0
2 94 84 77 1 2.7 21 11 7.361 49.58 62.57 28.34 23 0.75 1.86 0.42 31 71 1 1 1 0 0
4 95 91 81 0 2.6 5 4 7.374 40.43 70.3 25.57 24 0.72 1.1 0.65 33 80 1 1 1 0 0
4 93 87 81 1 3.9 14 9 7.386 40.98 70.45 25.1 26 0.62 1.1 0.68 35 84 0 0 1 1 0
6 95 90 80 0 15.8 22 17 7.389 38.54 72.38 26.51 30 0.74 1.54 0.48 34 98 0 1 1 0 0
2 95 89 85 1 0 19 7 7.351 47.55 62.67 29.65 21 0.62 1.37 0.45 34 81 1 0 0 0 0
4 95 92 90 0 0 12 7 7.377 37.76 74.41 25.53 21 0.55 1.18 0.59 31 73 0 0 0 0 0
4 95 90 87 0 0 7 9 7.385 38.56 70.48 26.78 29 0.78 1.67 0.47 31 76 0 0 0 0 0
5 96 91 85 0 3.8 10 4 7.374 40.43 77.54 25.57 26 0.8 1.32 0.52 35 79 0 0 0 0 0
5 94 91 83 0 3.6 7 9 7.416 37.59 79.65 25.67 30 0.61 1.35 0.45 36 83 0 0 1 0 0
1 94 90 80 0 2.8 9 7 7.362 49.54 70.24 28.67 28 0.56 1.07 0.52 32 87 0 0 0 0 0
1 93 87 81 1 0 5 13 7.354 50.4 65.89 28.67 31 0.67 1.52 0.44 35 79 0 1 1 0 0
1 90 86 80 1 3.6 8 10 7.359 46.5 62.12 32.42 25 0.58 1.52 0.4 33 89 0 0 1 0 0
1 91 83 72 1 2.4 17 12 7.361 55.8 62.43 30.65 32 0.87 1.4 0.62 36 90 0 0 1 1 0
The Pittsburgh Sleep Quality Index (PSQI) 
Instructions: The following questions relate to your usual sleep habits during the past month only. Your answers 
should indicate the 
most accurate reply for the majority of days and nights in the past month. Please answer all questions. During the 
past month, 
1. When have you usually gone to bed? ______________ 
2. How long (in minutes) has it taken you to fall asleep each night? ______________ 
3. When have you usually gotten up in the morning? ______________ 
4. How many hours of actual sleep do you get at night? (This may be different than the number of hours you spend 
in bed) _____________ 
5. During the past month, how often have you                           Not during         Less than      Once    or                    
Three or 
had trouble sleeping because you…                                            the past             once a            twice a                      
more times 
month (0 )        week (1)        week (2)                   week (3) 
a. Cannot get to sleep within 30 minutes 
b. Wake up in the middle of the night or early morning 
c. Have to get up to use the bathroom 
d. Cannot breathe comfortably 
e. Cough or snore loudly 
f. Feel too cold 
g. Feel too hot 
h. Have bad dreams 
i. Have pain 
j. Other reason(s), please describe, including how often you 
have had trouble sleeping because of this reason(s): 
6. During the past month, how often have you taken medicine 
(prescribed or “over the counter”) to help you sleep? 
7. During the past month, how often have you had trouble staying 
awake while driving, eating meals, or engaging in social activity? 
8. During the past month, how much of a problem has it been for 
you to keep up enthusiasm to get things done? 
                                                                                                                           Very        Fairly         Fairly        Very 
good (0)   good (1)     bad (2)      bad (3) 
9. During the past month, how would you rate your sleep 
quality overall? 
Component 1 #9 Score................................................................................................................................................... 
C1_______ 
Component 2 #2 Score ( 15min=0; 16-30 min=1; 31-60 min=2, >60 min=3) + #5a Score 
(if sum is equal 0=0; 1-2=1; 3-4=2; 5-6=3)......................................................................................... C2_______ 
Component 3 #4 Score (>7=0; 6-7=1; 5-6=2; <5=3).............................................................................................. 
C3_______ 
Component 4 (total # of hours asleep)/(total # of hours in bed) x 100 
>85%=0, 75%-84%=1, 65%-74%=2, <65%=3.................................................................................... C4_______ 
Component 5 Sum of Scores #5b to #5j (0=0; 1-9=1; 10-18=2; 19-27=3)............................................................. 
C5_______ 
Component 6 #6 Score .................................................................................................................................................. 
C6_______ 
Component 7 #7 Score + #8 Score (0=0; 1-2=1; 3-4=2; 5-6=3)............................................................................. 
C7_______
GLOBAL PSQI SCORE __________ 
EPWORTH SLEEPINESS SCALE FORM 
Instructions: Be as truthful as possible.  Print the form.  Read the situation in the first column; select your 
response from the second column; enter that number in the third column.  Total all of the entries in the 
third column and enter the total in the last box. 
Situation Responses Score 
 
Sitting and Reading 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
        
 
Watching Television 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
        
Sitting inactive in a public place, for 
example, a theater or a meeting 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
        
As a passenger in a car for an hour 
without a break  
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing  
3 = high chance of dozing 
        
 
Lying down to rest in the afternoon 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
        
 
Sitting and talking to someone 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
        
 
Sitting quietly after lunch when you’ve 
had no alcohol 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing  
3 = high chance of dozing 
        
 
In a car while stopped in traffic 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing  
3 = high chance of dozing 
        
 
TOTAL SCORE 
 
                
A score of 10 or greater indicates a possible sleep disorder.  Take the completed form to your doctor. 
Provided courtesy of  Narcolepsy Network, Inc.  110 Ripple Lane North Kingston, RI 02852 
Toll free 888-292-6522 Tel 401-667-2523 Fax 401-633-6567 
E-mail: narnet@narcolepsynetwork.org Website: www.narcolepsynetwork.org 
 
© The Associated Professional Sleep Societies, Westchester, IL. Johns MW. A new 
method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 
1991;14(6):540-545. 
CONSENT FORM
I Mr / Mrs / Miss / ____________________________ have 
understood the procedure read by the Doctors. I in my whole 
conscious awareness give consent for the procedure. I understand 
that the procedure is done in good faith for the best therapeutic 
results possible. I fully understand the consequences of the 
procedure. I can resign from the study at any point of time. 
Signature  :
Name :
Date and Time  :
Signature of Researcher :
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